MINUTES OF THE JANUARY 9-10, 2017
MEETING OF THE STATE OF OHIO BOARD OF PHARMACY

Monday, January 9, 2017

10:00 a.m. The Ohio State Board of Pharmacy convened in Room South B&C, 31st Floor, of the Vern Riffe Center for Government and the Arts, 77 South High Street, Columbus, Ohio, with the following members present:

Michael A. Moné, RPh, President; Joshua M. Cox, RPh; Curtis L. Passafume, Jr., RPh; Megan E. Marchal, RPh; Jennifer M. Rudell, RPh; Fred M. Weaver, RPh; Shawn C. Wilt, RPh and Kilee S. Yarosh, RPh

Also present were Steven Schierholt, Executive Director; Nicole Dehner, Chief Legal Counsel; Chad Garner, Director of OARRS; Chandra Galante, Director of Licensing; Eric Griffin, Director of Compliance and Enforcement; Steven Kochheiser, Assistant Attorney General and Cameron McNamee, Director of Policy and Communications.

Mr. Moné stated there was not a CPG Committee update.

Ms. Marchal stated there was nothing new to report regarding the PAPC Committee.

Ms. Galante provided the Licensing update noting the CE audit will now be a 100% check, two licensing coordinator positions will be posted by months’ end and touched base on the TDDD renewal.

Mr. Griffin provided the Compliance and Enforcement report.

Mr. Garner provided the OARRS/IT update.

Ms. Dehner and Mr. Kochheiser provided the Legal report.

R-2017-206 Ms. Marchal moved that the Board adopt the proposed Settlement presented by X-Gen Pharmaceuticals, Inc. The motion was seconded by Mr. Passafume and it was approved by the Board: Aye-7.

10:21 a.m. Mr. McNamee provided the Legislative update.

11:22 a.m. The Board recessed briefly.

11:32 a.m. The meeting reconvened in Room South B&C.
Mr. Passafume moved that Rules 4729-9-10, 4729-9-13, 4729-5-25 and 4729-18; 01, 02, 03 and 04 be approved as amended for filing with CSI and JCARR. The motion was seconded by Ms. Yarosh and approved by the Board: Aye-7.

Mr. Passafume moved that Rule 4729-5-10 be approved for refiling with JCARR. The motion was seconded by Ms. Marchal and approved by the Board: Aye-7.

Mr. Passafume moved that Rules 4729-37-03, 4729-9-14, and 4729-9-22 be approved for filing with JCARR. The motion was seconded by Ms. Rudell and approved by the Board: Aye-7.

Mr. Schierholt provided the Executive Director report.

The Board recessed for lunch.

The meeting reconvened in Room South B&C.

Mr. Moné announced that the following Settlement Agreement has been signed by all parties and is now effective:

IN THE MATTER OF:
CASE NOs.
2015-1850-A
2015-2018-A
2015-1694-A
2015-1671-A
2015-1666-A

Kroger #014942
c/o Karen Helmes, RPh
1014 Vine Street
Cincinnati, Ohio 45202
License No. 02-1044350

SETTLEMENT AGREEMENT WITH THE STATE OF OHIO BOARD OF PHARMACY

This Settlement Agreement (Agreement) is entered into by the State of Ohio Board of Pharmacy (OSBP) and Kroger #014942, for the purpose of resolving all issues between the parties relating to the OSBP investigation of (5) errors in dispensing’s by (3) staff pharmacists. Together, OSBP and Kroger #014942 are referred to hereinafter as “the parties.”

JURISDICTION
1. Pursuant to Section 4729.57 of the Ohio Revised Code and the rules adopted thereunder, the OSBP has the authority to suspend, revoke, or refuse to grant or renew any license issued pursuant to Section 4729.55 of the Ohio Revised Code to practice pharmacy the state of Ohio.

2. Kroger #014942 is a licensed Terminal Distributor of Dangerous Drugs under license number 02-1044350.
FACTS

1. On or about July 31, 2015, the OSBP initiated an investigation of Kroger #014942, Terminal Distributor of Dangerous Drugs license number 02-1044350, related to Kroger #014942’s five (5) errors in dispensing’s by three (3) staff pharmacists.

2. On or about June 16, 2016 the OSBP sent a Notice of Opportunity for Hearing to Kroger #014942, which outlined the allegations and provided notice of their right to a hearing, their rights in such hearing, and their right to submit contentions in writing.

3. On or about July 12, 2016, Kroger #014942 timely requested an administrative hearing, which was subsequently scheduled for December 7, 2016.

WHEREFORE, the parties desire to resolve the issues relating to the above-referenced findings without resorting to further administrative or judicial proceedings.

TERMS

NOW THEREFORE, in consideration of the mutual promises herein expressed, the parties knowingly and voluntarily agree as follows:

1. The recitals set forth above are incorporated in this Settlement Agreement as though fully set forth herein.

2. Kroger #014942 neither admits nor denies the allegations stated in the Notice of Opportunity for hearing letter dated June 16, 2016; however, the OSBP has evidence sufficient to sustain the allegations and hereby adjudicates the same.

3. Kroger #014942 agrees to continue education and training of its pharmacy staff in Best Practices.

4. Kroger #014942 agrees to continue quarterly education meetings.

5. Kroger #014942 agrees to pay to the OSBP the amount of $2,500.00, by means of a cashier’s check made payable to “Treasurer, State of Ohio,” mailed with the enclosed form to the OSBP, 77 South High Street, 17th Floor, Columbus, Ohio 43215-6126, no later than 30 days from the effective date of this Agreement.

6. Kroger #014942 agrees that all schedule II substances will continue to be double counted by the technicians with a third count being performed by the pharmacist and back-counted before the stock is returned to the lockable safe.

7. Kroger #014942 and Karen Helmes, RPh agree and acknowledge that this OSBP disciplinary action must be disclosed to the proper licensing authority of any state or jurisdiction in which Kroger #014942 currently holds a professional license, including the OSBP on renewal applications or applications for a new license.

8. Kroger #014942 agrees to comply with all federal and state requirements related to Terminal Distributors of Dangerous Drugs, including but not limited to, Ohio Revised Code Chapter
4729. and the Rules adopted thereunder, Chapter 3719. and the Rules adopted thereunder, Chapter 3715. and the Rules adopted thereunder as well as the “Federal Food, Drug, and Cosmetic Act,” 52 Stat. 1040 (1938), 21 U.S.C.A. 301 and Chapter 21, Section 360 of the United States Code, and Section 207.20 of the Code of Federal Regulations. Any violation by Kroger #014942 of the terms of one or more federal or state requirements may constitute sufficient grounds for further enforcement action related to any licenses granted to Kroger #014942 by the OSBP and will NOT discharge Kroger #014942 from any obligation under the terms of this Agreement.

9. Kroger #014942 agrees to pay all reasonable costs associated with the collection of any payment, and of the prosecution of any violation of this Agreement.

10. Kroger #014942 understands that it has the right to be represented by counsel for review and execution of this agreement.

11. This Agreement is binding upon any and all successors, assigns, affiliates, and subsidiaries of the parties or any other corporation through whom or with whom Kroger #014942 will operate.

12. Kroger #014942 specifically withdraws its request for a hearing in this matter, waives its opportunity to be heard pursuant to Chapter 119 of the Ohio Revised Code, and waives any right to an appeal.

13. This Agreement may be executed in counterparts or facsimiles, each of which shall be deemed an original, but all of which shall constitute one and the same instrument.

14. All parties to this Agreement understand that this document is a public record pursuant to Ohio Revised Code Section 149.43.

15. This Agreement contains the entire agreement between the parties, there being no other agreement of any kind, verbal or otherwise, which varies the terms of this Agreement.

R-2017-211 Mr. Moné announced that the following Settlement Agreement has been signed by all parties and is now effective:

IN THE MATTER OF:
CASE NOs.
2016-1107-A
2016-1021-A
2015-2024-A
2015-1708-A

Kroger #014934
c/o Warren Sizemore, RPh
1014 Vine Street
Cincinnati, Ohio 45202
License No. 02-1042350
SETTLEMENT AGREEMENT WITH THE STATE OF OHIO BOARD OF PHARMACY

This Settlement Agreement (Agreement) is entered into by the State of Ohio Board of Pharmacy (OSBP) and Kroger #014934, for the purpose of resolving all issues between the parties relating to the OSBP investigation of (4) errors in dispensing by staff pharmacist Isaac Pearson. Together, OSBP and Kroger #014934 are referred to hereinafter as “the parties.”

JURISDICTION

1. Pursuant to Section 4729.57 of the Ohio Revised Code and the rules adopted thereunder, the OSBP has the authority to suspend, revoke, or refuse to grant or renew any license issued pursuant to Section 4729.55 of the Ohio Revised Code to practice pharmacy the state of Ohio.

2. Kroger #014934 is a licensed Terminal Distributor of Dangerous Drugs under license number 02-1042350.

FACTS

1. On or about February 28, 2016, the OSBP initiated an investigation of Kroger #014934, Terminal Distributor of Dangerous Drugs license number 02-1042350, related to Kroger #014934’s four (4) errors in dispensing by staff pharmacist Isaac Pearson.

2. On or about June 16, 2016, the OSBP sent a Notice of Opportunity for Hearing to Kroger #014934, which outlined the allegations and provided notice of their right to a hearing, their rights in such hearing, and their right to submit contentions in writing.

3. On or about July 12, 2016, Kroger #014934 timely requested an administrative hearing, which was subsequently scheduled for December 7, 2016.

WHEREFORE, the parties desire to resolve the issues relating to the above-referenced findings without resorting to further administrative or judicial proceedings.

TERMS

NOW THEREFORE, in consideration of the mutual promises herein expressed, the parties knowingly and voluntarily agree as follows:

1. The recitals set forth above are incorporated in this Settlement Agreement as though fully set forth herein.

2. Kroger #014934 neither admits nor denies the allegations stated in the Notice of Opportunity for hearing letter dated June 16, 2016; however, the OSBP has evidence sufficient to sustain the allegations and hereby adjudicates the same.

3. Kroger #014934 agrees to pay to the OSBP the amount of $2,500.00, by means of a cashier’s check made payable to “Treasurer, State of Ohio,” mailed with the enclosed form to the OSBP, 77 South High Street, 17th Floor, Columbus, Ohio 43215-6126, no later than 30 days from the effective date of this Agreement.

4. Kroger #014934 agrees to continue education and training of its pharmacy staff in Best Practices.
5. Kroger #014934 agrees to continue quarterly education meetings.

6. Kroger #014934 and Warren Sizemore, RPh agree and acknowledge that this OSBP disciplinary action must be disclosed to the proper licensing authority of any state or jurisdiction in which Kroger #014934 currently holds a professional license, including the OSBP on renewal applications or applications for a new license.

7. Kroger #014934 agrees to comply with all federal and state requirements related to Terminal Distributors of Dangerous Drugs, including but not limited to, Ohio Revised Code Chapter 4729. and the Rules adopted thereunder, Chapter 3719. and the Rules adopted thereunder, Chapter 3715. and the Rules adopted thereunder as well as the “Federal Food, Drug, and Cosmetic Act,” 52 Stat. 1040 (1938), 21 U.S.C.A. 301 and Chapter 21, Section 360 of the United States Code, and Section 207.20 of the Code of Federal Regulations. Any violation by Kroger #014934 of the terms of one or more federal or state requirements may constitute sufficient grounds for further enforcement action related to any licenses granted to Kroger #014934 by the OSBP and will NOT discharge Kroger #014934 from any obligation under the terms of this Agreement.

8. Kroger #014934 agrees to pay all reasonable costs associated with the collection of any payment, and of the prosecution of any violation of this Agreement.

9. Kroger #014934 understands that it has the right to be represented by counsel for review and execution of this agreement.

10. This Agreement is binding upon any and all successors, assigns, affiliates, and subsidiaries of the parties or any other corporation through whom or with whom Kroger #014934 will operate.

11. Kroger #014934 specifically withdraws its request for a hearing in this matter, waives its opportunity to be heard pursuant to Chapter 119 of the Ohio Revised Code, and waives any right to an appeal.

12. This Agreement may be executed in counterparts or facsimiles, each of which shall be deemed an original, but all of which shall constitute one and the same instrument.

13. All parties to this Agreement understand that this document is a public record pursuant to Ohio Revised Code Section 149.43.

14. This Agreement contains the entire agreement between the parties, there being no other agreement of any kind, verbal or otherwise, which varies the terms of this Agreement.

R-2017-212 Mr. Moné announced that the following Settlement Agreement has been signed by all parties and is now effective:

IN THE MATTER OF:
CASE NO. 2015-2187-A
SETTLEMENT AGREEMENT WITH THE STATE OF OHIO BOARD OF PHARMACY

This Settlement Agreement (Agreement) is entered into by the State of Ohio Board of Pharmacy (OSBP) and Kroger #014915, for the purpose of resolving all issues between the parties relating to the OSBP investigation of dispensing expired medications. Together, OSBP and Kroger #014915 are referred to hereinafter as “the parties.”

JURISDICTION

1. Pursuant to Section 4729.57 of the Ohio Revised Code and the rules adopted thereunder, the OSBP has the authority to suspend, revoke, or refuse to grant or renew any license issued pursuant to Section 4729.55 of the Ohio Revised Code to practice pharmacy the state of Ohio.

2. Kroger #014915 is a licensed Terminal Distributor of Dangerous Drugs under license number 02-1041950.

FACTS

1. On or about December 10, 2015, the OSBP initiated an investigation of Kroger #014915, Terminal Distributor of Dangerous Drugs license number 02-1041950, related to Kroger #014915’s dispensing expired medications.

2. On or about June 17, 2016, the OSBP sent a Notice of Opportunity for Hearing to Kroger #014915, which outlined the allegations and provided notice of their right to a hearing, their rights in such hearing, and their right to submit contentions in writing.

3. On or about July 12, 2016, Kroger #014915 timely requested an administrative hearing, which was subsequently scheduled for December 7, 2016.

WHEREFORE, the parties desire to resolve the issues relating to the above-referenced findings without resorting to further administrative or judicial proceedings.

TERMS

NOW THEREFORE, in consideration of the mutual promises herein expressed, the parties knowingly and voluntarily agree as follows:

1. The recitals set forth above are incorporated in this Settlement Agreement as though fully set forth herein.

2. Kroger #014915 neither admits nor denies the allegations stated in the Notice of Opportunity for hearing letter dated June 17, 2016; however, the OSBP has evidence sufficient to sustain the allegations and hereby adjudicates the same.
3. Kroger #014915 agrees to pay to the OSBP the amount of $2,500.00, by means of a cashier’s check made payable to “Treasurer, State of Ohio,” mailed with the enclosed form to the OSBP, 77 South High Street, 17th Floor, Columbus, Ohio 43215-6126, no later than 30 days from the effective date of this Agreement.

4. Kroger #014915 agrees to continue education and training of its pharmacy staff in Best Practices.

5. Kroger #014915 agrees to continue with the assignment of continual monitoring and recording of expired drugs.

6. Kroger #014915 agrees to continue education and training of all pharmacy staff on recognition and removal of expired drugs.

7. Kroger #014915 and Christopher Forg, RPh agree and acknowledge that this OSBP disciplinary action must be disclosed to the proper licensing authority of any state or jurisdiction in which Kroger #014915 currently holds a professional license, including the OSBP on renewal applications or applications for a new license.

8. Kroger #014915 agrees to comply with all federal and state requirements related to Terminal Distributors of Dangerous Drugs, including but not limited to, Ohio Revised Code Chapter 4729. and the Rules adopted thereunder, Chapter 3719. and the Rules adopted thereunder, Chapter 3715. and the Rules adopted thereunder as well as the “Federal Food, Drug, and Cosmetic Act,” 52 Stat. 1040 (1938), 21 U.S.C.A. 301 and Chapter 21, Section 360 of the United States Code, and Section 207.20 of the Code of Federal Regulations. Any violation by Kroger #014915 of the terms of one or more federal or state requirements may constitute sufficient grounds for further enforcement action related to any licenses granted to Kroger #014915 by the OSBP and will NOT discharge Kroger #014915 from any obligation under the terms of this Agreement.

9. Kroger #014915 agrees to pay all reasonable costs associated with the collection of any payment, and of the prosecution of any violation of this Agreement.

10. Kroger #014915 understands that it has the right to be represented by counsel for review and execution of this agreement.

11. This Agreement is binding upon any and all successors, assigns, affiliates, and subsidiaries of the parties or any other corporation through whom or with whom Kroger #014915 will operate.

12. Kroger #014915 specifically withdraws its request for a hearing in this matter, waives its opportunity to be heard pursuant to Chapter 119 of the Ohio Revised Code, and waives any right to an appeal.

13. This Agreement may be executed in counterparts or facsimiles, each of which shall be deemed an original, but all of which shall constitute one and the same instrument.

14. All parties to this Agreement understand that this document is a public record pursuant to Ohio Revised Code Section 149.43.
15. This Agreement contains the entire agreement between the parties, there being no other agreement of any kind, verbal or otherwise, which varies the terms of this Agreement.

Mr. Moné announced that the following Settlement Agreement has been signed by all parties and is now effective:

**IN THE MATTER OF:**

**CASE NOs.**

2015-1527  
2015-1456  
2015-1181

**West Jefferson Urgent Care**  
**West Jefferson Internal Medicine**  
**c/o Michael Alexander, DO**  
95 E. Main Street  
West Jefferson, Ohio 43162  
**License Nos. 02-1944100**  
**WITHDRAWN 02-2515900**

**SETTLEMENT AGREEMENT WITH THE STATE OF OHIO BOARD OF PHARMACY**

This Settlement Agreement (Agreement) is entered into by the State of Ohio Board of Pharmacy (OSBP) and West Jefferson Urgent Care and Internal Medicine, for the purpose of resolving all issues between the parties relating to the OSBP investigation of the positive answer to the legal question on their TDDD application. Together, OSBP and West Jefferson Urgent Care and West Jefferson Internal Medicine are referred to hereinafter as “the parties.”

**JURISDICTION**

1. Pursuant to Section 4729.57 of the Ohio Revised Code and the rules adopted thereunder, the OSBP has the authority to suspend, revoke, or refuse to grant or renew any license issued pursuant to Section 4729.55 of the Ohio Revised Code to practice pharmacy the state of Ohio.

2. West Jefferson Urgent Care is a licensed Terminal Distributor of Dangerous Drugs under license number 02-1944100 and West Jefferson Internal Medicine submitted a Terminal Distributor of Dangerous Drugs application on or about April 25, 2015, pending license number 02-2515900.

**FACTS**

1. On or about June 4, 2014, the OSBP initiated an investigation of West Jefferson Urgent Care and West Jefferson Internal Medicine, Terminal Distributor of Dangerous Drugs license number 02-1944100 and pending license number 02-2515900, related to West Jefferson Urgent Care and West Jefferson Internal Medicine’s positive answer to the legal question on their TDDD application.
2. On or about May 9, 2016, the OSBP sent a Notice of Opportunity for Hearing to West Jefferson Urgent Care and a Notice of Opportunity for Hearing to West Jefferson Internal Medicine, which outlined the allegations and provided notice of their right to a hearing, their rights in such hearing, and their right to submit contentions in writing.

3. On or about May 24, 2016, West Jefferson Urgent Care and West Jefferson Internal Medicine timely requested an administrative hearing, which was subsequently scheduled for September 12, 2016.

WHEREFORE, the parties desire to resolve the issues relating to the above-referenced findings without resorting to further administrative or judicial proceedings.

TERMS

NOW THEREFORE, in consideration of the mutual promises herein expressed, the parties knowingly and voluntarily agree as follows:

1. The recitals set forth above are incorporated in this Settlement Agreement as though fully set forth herein.

2. West Jefferson Urgent Care and West Jefferson Internal Medicine neither admits nor denies the allegations stated in the Notice of Opportunity for Hearing letters dated May 9, 2016; however, the OSBP has evidence sufficient to sustain the allegations and hereby adjudicates the same.

3. West Jefferson Urgent Care agrees to pay to the OSBP the amount of $1,000.00, by means of a cashier’s check made payable to “Treasurer, State of Ohio,” mailed with the enclosed form to the OSBP, 77 South High Street, 17th Floor, Columbus, Ohio 43215-6126, no later than 30 days from the effective date of this Agreement.

4. West Jefferson Internal Medicine agrees to pay to the OSBP the amount of $500.00, by means of a cashier’s check made payable to “Treasurer, State of Ohio,” mailed with the enclosed form to the OSBP, 77 South High Street, 17th Floor, Columbus, Ohio 43215-6126, no later than 30 days from the effective date of this Agreement.

5. Eric Yoon agrees to complete, within 90 days from the effective date of this Agreement, 6 hours of approved continuing pharmacy education (0.6 CEUs), which may not also be used for license renewal. Copies of completed CEUs must be e-mailed to legal@pharmacy.ohio.gov.

6. Dr. Michael Alexander agrees to complete, within 90 days from the effective date of this Agreement, 6 hours of approved continuing medical education, which may not also be used for license renewal. Copies of completed CMEs must be e-mailed to legal@pharmacy.ohio.gov.

7. West Jefferson Internal Medicine’s request to withdraw their application submitted on or about April 25, 2015, is hereby approved.

8. West Jefferson Urgent Care’s Responsible Person, Dr. Michael Alexander, must submit a notarized statement to the OSBP monthly, for a period of one year from the effective date of this Agreement. The notarized statement must include a description of the number of times Dr.
Alexander was present at West Jefferson Urgent Care and a description of his duties while present at West Jefferson Urgent Care.

9. West Jefferson Urgent Care’s Responsible Person, Dr. Michael Alexander, must attend the State of Ohio Board of Pharmacy’s Responsible Person Roundtable within 90 days of the effective date of this agreement.

10. West Jefferson Urgent Care and West Jefferson Internal Medicine agree and acknowledge that this OSBP disciplinary action must be disclosed to the proper licensing authority of any state or jurisdiction in which they currently hold a professional license, including the OSBP on renewal applications or applications for a new license.

11. West Jefferson Urgent Care and West Jefferson Internal Medicine agrees to comply with all federal and state requirements related to Terminal Distributors of Dangerous Drugs, including but not limited to, Ohio Revised Code Chapter 4729. and the Rules adopted thereunder, Chapter 3719. and the Rules adopted thereunder, Chapter 3715. and the Rules adopted thereunder as well as the “Federal Food, Drug, and Cosmetic Act,” 52 Stat. 1040 (1938), 21 U.S.C.A. 301 and Chapter 21, Section 360 of the United States Code, and Section 207.20 of the Code of Federal Regulations. Any violation by West Jefferson Urgent Care and West Jefferson Internal Medicine of the terms of one or more federal or state requirements may constitute sufficient grounds for further enforcement action related to any licenses granted to West Jefferson Urgent Care and West Jefferson Internal Medicine by the OSBP and will NOT discharge West Jefferson Urgent Care and West Jefferson Internal Medicine from any obligation under the terms of this Agreement.

12. West Jefferson Urgent Care and West Jefferson Internal Medicine agree to pay all reasonable costs associated with the collection of any payment, and of the prosecution of any violation of this Agreement.

13. West Jefferson Urgent Care and West Jefferson Internal Medicine understands that it has the right to be represented by counsel for review and execution of this agreement.

14. This Agreement is binding upon any and all successors, assigns, affiliates, and subsidiaries of the parties or any other corporation through whom or with whom West Jefferson Urgent Care and West Jefferson Internal Medicine will operate.

15. West Jefferson Urgent Care and West Jefferson Internal Medicine specifically withdraws any request(s) for a hearing in these matter and waives opportunity to be heard pursuant to Chapter 119 of the Ohio Revised Code or any right to an appeal.

16. This Agreement may be executed in counterparts or facsimiles, each of which shall be deemed an original, but all of which shall constitute one and the same instrument.

17. All parties to this Agreement understand that this document is a public record pursuant to Ohio Revised Code Section 149.43.

18. This Agreement contains the entire agreement between the parties, there being no other agreement of any kind, verbal or otherwise, which varies the terms of this Agreement.
Mr. Moné announced that the following Settlement Agreement has been signed by all parties and is now effective:

IN THE MATTER OF:
CASE NO. 2015-1858-B

Keith Barga, RPh
2627 Kristi Lynne Lane
Toledo, Ohio 43617
License No. 03-3-11907

SETTLEMENT AGREEMENT WITH THE STATE OF OHIO BOARD OF PHARMACY

This Settlement Agreement (Agreement) is entered into by the State of Ohio Board of Pharmacy (OSBP) and Keith Barga, for the purpose of resolving all issues between the parties relating to the OSBP investigation of the error in dispensing of prescription number 2337372. Together, OSBP and Keith Barga are referred to hereinafter as “the parties.”

JURISDICTION
1. Pursuant to Section 4729.16 of the Ohio Revised Code and the rules adopted thereunder, the OSBP has the authority to suspend, revoke, or refuse to grant or renew any license issued pursuant to Section 4729.16 of the Ohio Revised Code to practice pharmacy as in the state of Ohio.

2. Keith Barga is a licensed pharmacist under license number 03-3-11907.

FACTS
1. On or about October 20, 2015, the OSBP initiated an investigation of Keith Barga, pharmacist license number 03-3-11907, related to Keith Barga’s error in dispensing of prescription number 2337372.

2. On or about August 24, 2016, the OSBP sent a Notice of Opportunity for Hearing to Keith Barga, which outlined the allegations and provided notice of his right to a hearing, his rights in such hearing, and his right to submit contentions in writing.

3. On or about September 27, 2016, Keith Barga timely requested an administrative hearing, which was subsequently scheduled for February 7, 2017.

WHEREFORE, the parties desire to resolve the issues relating to the above-referenced findings without resorting to further administrative or judicial proceedings.

TERMS
NOW THEREFORE, in consideration of the mutual promises herein expressed, the parties knowingly and voluntarily agree as follows:

1. The recitals set forth above are incorporated in this Settlement Agreement as though fully set forth herein.
2. Keith Barga neither admits nor denies the allegations stated in the Notice of Opportunity for hearing letter dated August 24, 2016; however, the OSBP has evidence sufficient to sustain the allegations and hereby adjudicates the same.

3. Keith Barga agrees to pay to the OSBP the amount of $500.00, by means of a cashier’s check made payable to “Treasurer, State of Ohio,” mailed with the enclosed form to the OSBP, 77 South High Street, 17th Floor, Columbus, Ohio 43215-6126, no later than 30 days from the effective date of this Agreement.

4. Keith Barga must obtain, within 90 days from the effective date of this Agreement, 6 hours of approved continuing pharmacy education (0.6 CEUs) in medication errors and/or patient safety, which may not also be used for license renewal. Copies of completed CEUs must be e-mailed to legal@pharmacy.ohio.gov.

5. Keith Barga agrees to pay all reasonable costs associated with the collection of any payment, and of the prosecution of any violation of this Agreement.

6. Keith Barga understands that he has the right to be represented by counsel for review and execution of this agreement.

7. Keith Barga agrees and acknowledges that this OSBP disciplinary action must be disclosed to the proper licensing authority of any state or jurisdiction in which he currently holds a professional license, including to the OSBP on renewal applications or applications for a new license.

8. Keith Barga withdraws his request for a hearing pursuant to Chapter 119 of the Ohio Revised Code and waives any right to an appeal.

9. This Agreement may be executed in counterparts or facsimiles, each of which shall be deemed an original, but all of which shall constitute one and the same instrument.

10. All parties to this Agreement understand that this document is a public record pursuant to Ohio Revised Code Section 149.43.

11. This Agreement contains the entire agreement between the parties, there being no other agreement of any kind, verbal or otherwise, which varies the terms of this Agreement.

R-2017-215

Mr. Moné announced that the following Settlement Agreement has been signed by all parties and is now effective:

IN THE MATTER OF:
CASE NO. 2016-1114-B

Carly Campbell
3422 Mink Street
Mount Vernon, Ohio 43050
License No. 03-3-26843
SETTLEMENT AGREEMENT WITH THE STATE OF OHIO BOARD OF PHARMACY

This Settlement Agreement (Agreement) is entered into by the State of Ohio Board of Pharmacy (OSBP) and Carly Campbell, for the purpose of resolving all issues between the parties relating to the OSBP investigation of the error in dispensing of RX#1322767. Together, OSBP and Carly Campbell are referred to hereinafter as “the parties.”

JURISDICTION

1. Pursuant to Section 4729.16 of the Ohio Revised Code and the rules adopted thereunder, the OSBP has the authority to suspend, revoke, or refuse to grant or renew any license issued pursuant to Section 4729.16 of the Ohio Revised Code to practice pharmacy as in the state of Ohio.

2. Carly Campbell is a licensed pharmacist under license number 03-3-26843.

FACTS

1. On or about February 10, 2016, the OSBP initiated an investigation of Carly Campbell, pharmacist license number 03-3-26843, related to Carly Campbell’s error in dispensing of prescription number 1322767.

2. On or about November 22, 2016 the OSBP sent a Notice of Opportunity for Hearing to Carly Campbell, which outlined the allegations and provided notice of her right to a hearing, her rights in such hearing, and her right to submit contentions in writing.

WHEREFORE, the parties desire to resolve the issues relating to the above-referenced findings without resorting to further administrative or judicial proceedings.

TERMS

NOW THEREFORE, in consideration of the mutual promises herein expressed, the parties knowingly and voluntarily agree as follows:

1. The recitals set forth above are incorporated in this Settlement Agreement as though fully set forth herein.

2. Carly Campbell neither admits nor denies the allegations stated in the Notice of Opportunity for hearing letter dated November 22, 2016; however, the OSBP has evidence sufficient to sustain the allegations and hereby adjudicates the same.

3. Carly Campbell agrees to pay to the OSBP the amount of $500.00, by means of a cashier’s check made payable to “Treasurer, State of Ohio,” mailed with the enclosed form to the OSBP, 77 South High Street, 17th Floor, Columbus, Ohio 43215-6126, no later than 30 days from the effective date of this Agreement.

4. Carly Campbell must obtain, within 90 days from the effective date of this Agreement, 6 hours of approved continuing pharmacy education (0.6 CEUs) in medication errors and/or patient
safety, which may not also be used for license renewal. Copies of completed CEUs must be e-mailed to legal@pharmacy.ohio.gov.

5. Carly Campbell agrees to pay all reasonable costs associated with the collection of any payment, and of the prosecution of any violation of this Agreement.

6. Carly Campbell understands that she has the right to be represented by counsel for review and execution of this agreement.

7. Carly Campbell agrees and acknowledges that this OSBP disciplinary action must be disclosed to the proper licensing authority of any state or jurisdiction in which she currently holds a professional license, including to the OSBP on renewal applications or applications for a new license.

8. Carly Campbell waives any request for a hearing in this matter and an opportunity to be heard pursuant to Chapter 119 of the Ohio Revised Code, as well as any right to appeal.

9. This Agreement may be executed in counterparts or facsimiles, each of which shall be deemed an original, but all of which shall constitute one and the same instrument.

10. All parties to this Agreement understand that this document is a public record pursuant to Ohio Revised Code Section 149.43.

11. This Agreement contains the entire agreement between the parties, there being no other agreement of any kind, verbal or otherwise, which varies the terms of this Agreement.

Mr. Moné announced that the following Settlement Agreement has been signed by all parties and is now effective:

IN THE MATTER OF:
CASE NO. 2016-1536

South Russell Veterinary Hospital, Inc.
c/o Lori Bieber
5210-C Chillicothe Road
Chargin Falls, OH 44022

PENDING License No. 02-2612150

SETTLEMENT AGREEMENT WITH THE STATE OF OHIO BOARD OF PHARMACY

This Settlement Agreement (Agreement) is entered into by the State of Ohio Board of Pharmacy (OSBP) and South Russell Veterinary Hospital, Inc., for the purpose of resolving all issues between the parties relating to the OSBP investigation of the negative answer to the legal question on their Terminal Distributor of Dangerous Drugs application. Together, OSBP and South Russell Veterinary Hospital, Inc. are referred to hereinafter as “the parties.”

JURISDICTION
1. Pursuant to Section 4729.57 of the Ohio Revised Code and the rules adopted thereunder, the OSBP has the authority to suspend, revoke, or refuse to grant or renew any license issued pursuant to Section 4729.55 of the Ohio Revised Code to practice pharmacy the state of Ohio.

2. South Russell Veterinary Hospital, Inc. is a licensed Terminal Distributor of Dangerous Drugs under license number 02-2612150.

FACTS

1. On or about May 18, 2016, the OSBP initiated an investigation of South Russell Veterinary Hospital, Inc., Terminal Distributor of Dangerous Drugs license number 02-2612150, related to South Russell Veterinary Hospital, Inc.’s negative answer to the legal question on their Terminal Distributor of Dangerous Drugs application.

2. On or about November 21, 2016, the OSBP sent a Notice of Opportunity for Hearing to South Russell Veterinary Hospital, Inc., which outlined the allegations and provided notice of their right to a hearing, their rights in such hearing, and their right to submit contentions in writing.

WHEREFORE, the parties desire to resolve the issues relating to the above-referenced findings without resorting to further administrative or judicial proceedings.

TERMS

NOW THEREFORE, in consideration of the mutual promises herein expressed, the parties knowingly and voluntarily agree as follows:

1. The recitals set forth above are incorporated in this Settlement Agreement as though fully set forth herein.

2. South Russell Veterinary Hospital, Inc. neither admits nor denies the allegations stated in the Notice of Opportunity for hearing letter dated November 21, 2016; however, the OSBP has evidence sufficient to sustain the allegations and hereby adjudicates the same.

3. South Russell Veterinary Hospital, Inc. agrees to pay to the OSBP a monetary penalty in the amount of $500.00, by means of a cashier’s check made payable to “Treasurer, State of Ohio,” mailed with the enclosed form to the OSBP, 77 South High Street, 17th Floor, Columbus, Ohio 43215-6126, no later than 30 days from the effective date of this Agreement.

4. South Russell Veterinary Hospital, Inc.’s Terminal Distributor of Dangerous Drugs license will be issued upon receipt of this Agreement and payment of the monetary penalty.

5. South Russell Veterinary Hospital, Inc. and Lori Bieber agree and acknowledge that this OSBP disciplinary action must be disclosed to the proper licensing authority of any state or jurisdiction in which South Russell Veterinary Hospital, Inc. currently holds a professional license, including the OSBP on renewal applications or applications for a new license.

6. South Russell Veterinary Hospital, Inc. agrees to comply with all federal and state requirements related to Terminal Distributors of Dangerous Drugs, including but not limited to, Ohio Revised Code Chapter 4729. and the Rules adopted thereunder, Chapter 3719. and the Rules adopted thereunder, Chapter 3715. and the Rules adopted thereunder as well as the “Federal
Food, Drug, and Cosmetic Act,” 52 Stat. 1040 (1938), 21 U.S.C.A. 301 and Chapter 21, Section 360 of the United States Code, and Section 207.20 of the Code of Federal Regulations. Any violation by South Russell Veterinary Hospital, Inc. of the terms of one or more federal or state requirements may constitute sufficient grounds for further enforcement action related to any licenses granted to South Russell Veterinary Hospital, Inc. by the OSBP and will NOT discharge South Russell Veterinary Hospital, Inc. from any obligation under the terms of this Agreement.

7. South Russell Veterinary Hospital, Inc. agrees to pay all reasonable costs associated with the collection of any payment, and of the prosecution of any violation of this Agreement.

8. South Russell Veterinary Hospital, Inc. understands that it has the right to be represented by counsel for review and execution of this agreement.

9. This Agreement is binding upon any and all successors, assigns, affiliates, and subsidiaries of the parties or any other corporation through whom or with whom South Russell Veterinary Hospital, Inc. will operate.

10. South Russell Veterinary Hospital, Inc. waives any request for a hearing in this matter and an opportunity to be heard pursuant to Chapter 119 of the Ohio Revised Code, and waives any right to an appeal.

11. This Agreement may be executed in counterparts or facsimiles, each of which shall be deemed an original, but all of which shall constitute one and the same instrument.

12. All parties to this Agreement understand that this document is a public record pursuant to Ohio Revised Code Section 149.43.

13. This Agreement contains the entire agreement between the parties, there being no other agreement of any kind, verbal or otherwise, which varies the terms of this Agreement.

R-2017-217

Mr. Moné announced that the following Settlement Agreement has been signed by all parties and is now effective:

IN THE MATTER OF:

CASE NO. 2016-1320

Summit Pain Specialists, Inc.
4302 Allen Road, #300
Stow, Ohio 44224
License No. 02-2052400

SETTLEMENT AGREEMENT WITH THE STATE OF OHIO BOARD OF PHARMACY

This Settlement Agreement (Agreement) is entered into by the State of Ohio Board of Pharmacy (OSBP) and Summit Pain Specialists, Inc., for the purpose of resolving all issues between the parties relating to the OSBP investigation of the affirmative answers to both legal questions on
Summit Pain Specialist, Inc.’s change of ownership application. Together, OSBP and Summit Pain Specialists, Inc. are referred to hereinafter as “the parties.”

JURISDICTION
1. Pursuant to Section 4729.57 of the Ohio Revised Code and the rules adopted thereunder, the OSBP has the authority to suspend, revoke, or refuse to grant or renew any license issued pursuant to Section 4729.55 of the Ohio Revised Code to practice pharmacy the state of Ohio.

2. Summit Pain Specialists, Inc. is a licensed Terminal Distributor of Dangerous Drugs with a Pain Management Clinic Classification under license number 02-2052400.

FACTS
1. On or about March 16, 2016, the OSBP initiated an investigation of Summit Pain Specialists, Inc., Terminal Distributor of Dangerous Drugs license number 02-2052400, related to Summit Pain Specialists, Inc.’s affirmative answers to both legal questions on its change of ownership application.

2. On or about August 19, 2016, the OSBP sent a Notice of Opportunity for Hearing to Summit Pain Specialists, Inc., which outlined the allegations and provided notice of their right to a hearing, their rights in such hearing, and their right to submit contentions in writing.

WHEREFORE, the parties desire to resolve the issues relating to the above-referenced findings without resorting to further administrative or judicial proceedings.

TERMS
NOW THEREFORE, in consideration of the mutual promises herein expressed, the parties knowingly and voluntarily agree as follows:

1. The recitals set forth above are incorporated in this Settlement Agreement as though fully set forth herein.

2. Summit Pain Specialists, Inc. neither admits nor denies the allegations stated in the Notice of Opportunity for hearing letter dated August 19, 2016; however, the OSBP has evidence sufficient to sustain the allegations and hereby adjudicates the same.

3. SUMMIT PAIN SPECIALISTS, INC. PERMANENTLY AND VOLUNTARILY SURRENDERS, WITH DISCIPLINE PENDING, TO THE STATE OF OHIO BOARD OF PHARMACY LICENSE NO. 02-2052400 INCLUDING REGISTRATION TO SELL, DELIVER OR DISTRIBUTE DANGEROUS DRUGS.


5. Summit Pain Specialists, Inc. agrees to pay all reasonable costs associated with the collection of any payment, and of the prosecution of any violation of this Agreement.
6. Summit Pain Specialists, Inc. understands that it has the right to be represented by counsel for review and execution of this agreement.

7. This Agreement is binding upon any and all successors, assigns, affiliates, and subsidiaries of the parties or any other corporation through whom or with whom Summit Pain Specialists, Inc. will operate.

8. Summit Pain Specialists, Inc. waives any opportunity to be heard pursuant to Chapter 119. of the Ohio Revised Code any right to an appeal.

9. This Agreement may be executed in counterparts or facsimiles, each of which shall be deemed an original, but all of which shall constitute one and the same instrument.

10. All parties to this Agreement understand that this document is a public record pursuant to Ohio Revised Code Section 149.43.

11. This Agreement contains the entire agreement between the parties, there being no other agreement of any kind, verbal or otherwise, which varies the terms of this Agreement.

Mr. Moné announced that the following Settlement Agreement has been signed by all parties and is now effective:

IN THE MATTER OF:
CASE NO. 2016-1232-B

Andrew Longmate
8477 Churchill Downs Court
Holland, Ohio 43528
License No. 03234200

SETTLEMENT AGREEMENT WITH THE STATE OF OHIO BOARD OF PHARMACY

This Settlement Agreement (Agreement) is entered into by the State of Ohio Board of Pharmacy (OSBP) and Andrew Longmate, for the purpose of resolving all issues between the parties relating to the OSBP investigation of the error in dispensing of prescription number 235959. Together, OSBP and Andrew Longmate are referred to hereinafter as “the parties.”

JURISDICTION

1. Pursuant to Section 4729.16 of the Ohio Revised Code and the rules adopted thereunder, the OSBP has the authority to suspend, revoke, or refuse to grant or renew any license issued pursuant to Section 4729.16 of the Ohio Revised Code to practice pharmacy as in the state of Ohio.

2. Andrew Longmate is a licensed pharmacist under license number 03234200.
FACTS

1. On or about March 2, 2016, the OSBP initiated an investigation of Andrew Longmate, pharmacist license number 03234200, related to Andrew Longmate’s error in dispensing of prescription number 235959.

2. On or about December 8, 2016, the OSBP sent a Notice of Opportunity for Hearing to Andrew Longmate, which outlined the allegations and provided notice of his right to a hearing, his rights in such hearing, and his right to submit contentions in writing.

WHEREFORE, the parties desire to resolve the issues relating to the above-referenced findings without resorting to further administrative or judicial proceedings.

TERMS

NOW THEREFORE, in consideration of the mutual promises herein expressed, the parties knowingly and voluntarily agree as follows:

1. The recitals set forth above are incorporated in this Settlement Agreement as though fully set forth herein.

2. Andrew Longmate neither admits nor denies the allegations stated in the Notice of Opportunity for hearing letter dated December 8, 2016; however, the OSBP has evidence sufficient to sustain the allegations and hereby adjudicates the same.

3. Andrew Longmate agrees to pay to the OSBP the amount of $500.00, by means of a cashier’s check made payable to “Treasurer, State of Ohio,” mailed with the enclosed form to the OSBP, 77 South High Street, 17th Floor, Columbus, Ohio 43215-6126, no later than 30 days from the effective date of this Agreement.

4. Andrew Longmate must obtain, within 90 days from the effective date of this Agreement, 6 hours of approved continuing pharmacy education (0.6 CEUs) in medication errors and/or patient safety, which may not also be used for license renewal. Copies of completed CEUs must be e-mailed to legal@pharmacy.ohio.gov.

5. Andrew Longmate agrees to pay all reasonable costs associated with the collection of any payment, and of the prosecution of any violation of this Agreement.

6. Andrew Longmate understands that he has the right to be represented by counsel for review and execution of this agreement.

7. Andrew Longmate agrees and acknowledges that this OSBP disciplinary action must be disclosed to the proper licensing authority of any state or jurisdiction in which he currently holds a professional license, including to the OSBP on renewal applications or applications for a new license.

8. Andrew Longmate waives his right to a hearing under to Chapter 119 of the Ohio Revised Code and waives any right to appeal.
9. This Agreement may be executed in counterparts or facsimiles, each of which shall be deemed an original, but all of which shall constitute one and the same instrument.

10. All parties to this Agreement understand that this document is a public record pursuant to Ohio Revised Code Section 149.43.

11. This Agreement contains the entire agreement between the parties, there being no other agreement of any kind, verbal or otherwise, which varies the terms of this Agreement.

Mr. Moné announced that the following Settlement Agreement has been signed by all parties and is now effective:

**IN THE MATTER OF:**
**CASE NO. 2013-1974**

**X-Gen Pharmaceuticals, Inc.**
300 Daniel Zenker Drive
Horseheads, NY 14845
WDDD License No. 01-2037200

**SETTLEMENT AGREEMENT WITH THE STATE OF OHIO BOARD OF PHARMACY**

By stipulation of the parties, the State of Ohio Board of Pharmacy (Board) and X-Gen Pharmaceuticals, Inc. (the parties) agree to the following amendments to the Board’s Adjudication Order dated June 7, 2016 as part of the terms for X-Gen Pharmaceutical’s dismissal of Appeal in the Court of Common Pleas in Franklin County, Ohio Case No. 16-CV-5818:

Finding of Fact #1 is modified to read as follows:
Records of the Board of Pharmacy indicated that Susan Badia was the president, and Richard Park was the responsible person at, X-Gen Pharmaceuticals, Inc., Ohio Wholesale Distributor of Dangerous Drugs License No. 01-2037200, pursuant to Sections 4729. of the Ohio Revised Code within the meaning of Section 4729.56 of the Ohio Revised Code.

Finding of Fact #2 is removed.
Conclusion of Law #1 is removed.
Conclusion of Law #2 is removed.
The Board’s Amended Order dated with the effective date of this agreement is attached hereto and incorporated as though fully set forth herein as Attachment A.

Additional terms of the Settlement Agreement in the dismissal of above-reference Case No. 16-CV-5818 include:

1. The Board shall report these modifications of the aforementioned Order to the National Practitioner Data Bank established by Title IV, Public Law 99-660, the Health Care Quality Improvement Act of 1986, as amended, and to all boards, agencies, authorities, and other entities, no matter the jurisdiction, to which the aforementioned Order was previously reported.
2. The parties waive any right and/or claim they might have to an award of attorney fees in this appeal.

3. X-Gen Pharmaceuticals, Inc. having deposited $4,000 with the clerk of court as security, the clerk of court is hereby ordered to release said security in said amount to the Board of Pharmacy in the form of a check made payable to the State of Ohio Board of Pharmacy. The check may be mailed addressed to: Steven R. Kochheiser, Assistant Attorney General, 30 East Broad Street, 26th Floor, Columbus, OH 43215.

4. The Dismissal with Prejudice and instructions to the Court shall serve for all purposes as proof of payment by X-Gen Pharmaceuticals, Inc. of the $4,000 penalty imposed by the aforementioned Order dated of the State of Ohio Board of Pharmacy.

5. X-Gen Pharmaceuticals, Inc. waives any right to appeal the Amended Order as set forth in Section 119.12 of the Revised Code.

IN WITNESS WHEREOF, the parties to this Agreement have executed it and/or cause it to be executed by their duly authorized representatives.

R-2017-220 Mr. Moné announced that the following Settlement Agreement has been signed by all parties and is now effective:

IN THE MATTER OF:
CASE NO. 2015-1436

Matthew Erick
782 Tim Tam Avenue
Gahanna, Ohio 43230
License No. 03-2-19632

SETTLEMENT AGREEMENT WITH THE STATE OF OHIO BOARD OF PHARMACY

This Settlement Agreement (Agreement) is entered into by the State of Ohio Board of Pharmacy (OSBP) and Matthew Erick, for the purpose of resolving all issues between the parties relating to the OSBP investigation of the violation of a Settlement Agreement. Together, OSBP and Matthew Erick are referred to hereinafter as “the parties.”

JURISDICTION

1. Pursuant to Section 4729.16 of the Ohio Revised Code and the rules adopted thereunder, the OSBP has the authority to suspend, revoke, or refuse to grant or renew any license issued pursuant to Section 4729.16 of the Ohio Revised Code to practice pharmacy as in the state of Ohio.

2. Matthew Erick is a licensed pharmacist under license number 03-2-19632.

FACTS
1. On or about June 21, 2016, the OSBP initiated an investigation of Matthew Erick, pharmacist license number 03219632, related to Matthew Erick’s violation of his Settlement Agreement dated February 1, 2016.

2. On or about August 19, 2016, the OSBP sent a Notice of Opportunity for Hearing to Matthew Erick, which outlined the allegations and provided notice of his right to a hearing, his rights in such hearing, and his right to submit contentions in writing.

WHEREFORE, the parties desire to resolve the issues relating to the above-referenced findings without resorting to further administrative or judicial proceedings.

TERMS
NOW THEREFORE, in consideration of the mutual promises herein expressed, the parties knowingly and voluntarily agree as follows:

1. The recitals set forth above are incorporated in this Settlement Agreement as though fully set forth herein.

2. Matthew Erick neither admits nor denies the allegations stated in the Notice of Opportunity for hearing letter dated August 19, 2016; however, the OSBP has evidence sufficient to sustain the allegations and hereby adjudicates the same.

3. Matthew Erick agrees to pay the original $250 fine owed from the settlement agreement dated February 2, 2016 as well as the reasonable costs associated with the collection of any payment, and of the prosecution of any violation of that Agreement as set forth in term eight (8) of that agreement. The OSBP's investigative and prosecution costs amount to $131, for a total to be paid to the Board of $381.

4. MATTHEW ERICK PERMANENTLY AND VOLUNTARILY SURRENDERS TO THE STATE OF OHIO BOARD OF PHARMACY HIS LICENSE AND REGISTRATION TO PRACTICE PHARMACY, LICENSE NO. 03219632, WITH DISCIPLINE PENDING.

5. Matthew Erick may never reapply for any license issued by the State of Ohio Board of Pharmacy pursuant to Chapters 3719., 3796., and 4729. of the Revised Code.

6. Matthew Erick agrees to pay all reasonable costs associated with the collection of any payment, and of the prosecution of any violation of this Agreement.

7. Matthew Erick understands that he has the right to be represented by counsel for review and execution of this agreement.

8. Matthew Erick agrees and acknowledges that this OSBP disciplinary action must be disclosed to the proper licensing authority of any state or jurisdiction in which he currently holds a professional license.

9. Matthew Erick waives his right to request a hearing in this matter pursuant to Chapter 119. of the Ohio Revised Code and waives any appeal rights.
10. This Agreement may be executed in counterparts or facsimiles, each of which shall be deemed an original, but all of which shall constitute one and the same instrument.

11. All parties to this Agreement understand that this document is a public record pursuant to Ohio Revised Code Section 149.43.

12. This Agreement contains the entire agreement between the parties, there being no other agreement of any kind, verbal or otherwise, which varies the terms of this Agreement.

Mr. Moné announced that the following Settlement Agreement has been signed by all parties and is now effective:

IN THE MATTER OF:
CASE NO. 2015-1183

Nicolene Engelbrecht
4014 Whitham Hill Drive, Apt #95
Corvallis, OR 97330
License No. 03230721

SETTLEMENT AGREEMENT WITH THE STATE OF OHIO BOARD OF PHARMACY

This Settlement Agreement (Agreement) is entered into by the State of Ohio Board of Pharmacy (OSBP) and Nicolene Engelbrecht, for the purpose of resolving all issues between the parties relating to the OSBP investigation of Nicolene Engelbrecht’s continuing education units. Together, OSBP and Nicolene Engelbrecht are referred to hereinafter as “the parties.”

JURISDICTION

1. Pursuant to Section 4729.16 of the Ohio Revised Code and the rules adopted thereunder, the OSBP has the authority to suspend, revoke, or refuse to grant or renew any license issued pursuant to Section 4729.16 of the Ohio Revised Code to practice pharmacy as in the state of Ohio.

2. Nicolene Engelbrecht is a licensed pharmacist under license number 03230721.

FACTS

1. On or about February 25, 2015, the OSBP initiated an investigation of Nicolene Engelbrecht, pharmacist license number 03230721, related to Nicolene Engelbrecht’s continuing education units.

2. On or about December 1, 2016, the OSBP sent a Notice of Opportunity for Hearing to Nicolene Engelbrecht, which outlined the allegations and provided notice of her right to a hearing, her rights in such hearing, and her right to submit contentions in writing.

WHEREFORE, the parties desire to resolve the issues relating to the above-referenced findings without resorting to further administrative or judicial proceedings.
TERMS

NOW THEREFORE, in consideration of the mutual promises herein expressed, the parties knowingly and voluntarily agree as follows:

1. The recitals set forth above are incorporated in this Settlement Agreement as though fully set forth herein.

2. Nicolene Engelbrecht neither admits nor denies the allegations stated in the Notice of Opportunity for hearing letter dated December 1, 2016; however, the OSBP has evidence sufficient to sustain the allegations and hereby adjudicates the same.

3. Nicolene Engelbrecht agrees to pay to the OSBP the amount of $500.00, by means of a cashier’s check made payable to “Treasurer, State of Ohio,” mailed with the enclosed form to the OSBP, 77 South High Street, 17th Floor, Columbus, Ohio 43215-6126, no later than 30 days from the effective date of this Agreement.

4. Nicolene Engelbrecht must obtain, within 90 days from the effective date of this Agreement, 3 hours of approved continuing pharmacy education (0.3 CEUs) which may not also be used for license renewal. Copies of completed CEUs must be e-mailed to legal@pharmacy.ohio.gov.

5. Nicolene Engelbrecht agrees to pay all reasonable costs associated with the collection of any payment, and of the prosecution of any violation of this Agreement.

6. Nicolene Engelbrecht understands that she has the right to be represented by counsel for review and execution of this agreement.

7. Nicolene Engelbrecht agrees and acknowledges that this OSBP disciplinary action must be disclosed to the proper licensing authority of any state or jurisdiction in which she currently holds a professional license, including to the OSBP on renewal applications or applications for a new license.

8. Nicolene Engelbrecht waives her right to a hearing under Chapter 119. of the Ohio Revised Code and waives any right to appeal this matter.

9. This Agreement may be executed in counterparts or facsimiles, each of which shall be deemed an original, but all of which shall constitute one and the same instrument.

10. All parties to this Agreement understand that this document is a public record pursuant to Ohio Revised Code Section 149.43.

11. This Agreement contains the entire agreement between the parties, there being no other agreement of any kind, verbal or otherwise, which varies the terms of this Agreement.

Mr. Moné announced that the following Settlement Agreement has been signed by all parties and is now effective:
IN THE MATTER OF:  
CASE NO. 2015-2231

OhioHealth Cancer Physicians  
c/o Dr. Robert Exten, Jr.  
475 Lexington Avenue  
Mansfield, Ohio 44907  
PENDING License No. 02-2573400

SETTLEMENT AGREEMENT WITH THE STATE OF OHIO BOARD OF PHARMACY

This Settlement Agreement (Agreement) is entered into by the State of Ohio Board of Pharmacy (OSBP) and OhioHealth Cancer Physicians, for the purpose of resolving all issues between the parties relating to the OSBP investigation of the negative answer to the legal question on their Terminal Distributor of Dangerous Drugs Application. Together, OSBP and OhioHealth Cancer Physicians are referred to hereinafter as “the parties.”

JURISDICTION

1. Pursuant to Section 4729.57 of the Ohio Revised Code and the rules adopted thereunder, the OSBP has the authority to suspend, revoke, or refuse to grant or renew any license issued pursuant to Section 4729.55 of the Ohio Revised Code to practice pharmacy the state of Ohio.


FACTS

1. On or about December 14, 2015, the OSBP initiated an investigation of OhioHealth Cancer Physicians, Terminal Distributor of Dangerous Drugs pending license number 02-2573400, related to OhioHealth Cancer Physicians’ negative answer to the legal question on their Terminal Distributor of Dangerous Drugs Application.

2. On or about November 23, 2016, the OSBP sent a Notice of Opportunity for Hearing to OhioHealth Cancer Physicians, which outlined the allegations and provided notice of their right to a hearing, their rights in such hearing, and their right to submit contentions in writing.

WHEREFORE, the parties desire to resolve the issues relating to the above-referenced findings without resorting to further administrative or judicial proceedings.

TERMS

NOW THEREFORE, in consideration of the mutual promises herein expressed, the parties knowingly and voluntarily agree as follows:

1. The recitals set forth above are incorporated in this Settlement Agreement as though fully set forth herein.

2. OhioHealth Cancer Physicians neither admits nor denies the allegations stated in the Notice of Opportunity for Hearing letter dated November 23, 2016; however, the OSBP has evidence sufficient to sustain the allegations and hereby adjudicates the same.
3. OhioHealth Cancer Physicians agrees to pay to the OSBP the amount of $1,000.00, by means of a cashier’s check made payable to “Treasurer, State of Ohio,” mailed with the enclosed form to the OSBP, 77 South High Street, 17th Floor, Columbus, Ohio 43215-6126, no later than 30 days from the effective date of this Agreement.

4. OhioHealth Cancer Physicians Terminal Distributor of Dangerous Drugs license will be issued upon receipt of a corrected application, application fee, and fine payment.

5. OhioHealth Cancer Physicians and Dr. Robert Exten, Jr. agree and acknowledge that this OSBP disciplinary action must be disclosed to the proper licensing authority of any state or jurisdiction in which OhioHealth Cancer Physicians currently holds a professional license, including the OSBP on renewal applications or applications for a new license.

6. OhioHealth Cancer Physicians agrees to comply with all federal and state requirements related to Terminal Distributors of Dangerous Drugs, including but not limited to, Ohio Revised Code Chapter 4729. and the Rules adopted thereunder, Chapter 3719. and the Rules adopted thereunder, Chapter 3715. and the Rules adopted thereunder as well as the “Federal Food, Drug, and Cosmetic Act,” 52 Stat. 1040 (1938), 21 U.S.C.A. 301 and Chapter 21, Section 360 of the United States Code, and Section 207.20 of the Code of Federal Regulations. Any violation by OhioHealth Cancer Physicians of the terms of one or more federal or state requirements may constitute sufficient grounds for further enforcement action related to any licenses granted to OhioHealth Cancer Physicians by the OSBP and will NOT discharge OhioHealth Cancer Physicians from any obligation under the terms of this Agreement.

7. OhioHealth Cancer Physicians agrees to pay all reasonable costs associated with the collection of any payment, and of the prosecution of any violation of this Agreement.

8. OhioHealth Cancer Physicians understands that it has the right to be represented by counsel for review and execution of this agreement.

9. This Agreement is binding upon any and all successors, assigns, affiliates, and subsidiaries of the parties or any other corporation through whom or with whom OhioHealth Cancer Physicians will operate.

10. OhioHealth Cancer Physicians waives any request for a hearing in this matter and an opportunity to be heard pursuant to Chapter 119 of the Ohio Revised Code, and specifically waives any right to an appeal.

11. This Agreement may be executed in counterparts or facsimiles, each of which shall be deemed an original, but all of which shall constitute one and the same instrument.

12. All parties to this Agreement understand that this document is a public record pursuant to Ohio Revised Code Section 149.43.

13. This Agreement contains the entire agreement between the parties, there being no other agreement of any kind, verbal or otherwise, which varies the terms of this Agreement.
Mr. Moné announced that the following Settlement Agreement has been signed by all parties and is now effective:

**IN THE MATTER OF:**
**CASE NO. 2015-1977**

**Jacklyn Cropper**
562 49th Street SW
Canton, Ohio 44706
License No. 03-3-24131

**SETTLEMENT AGREEMENT WITH THE STATE OF OHIO BOARD OF PHARMACY**

This Settlement Agreement (Agreement) is entered into by the State of Ohio Board of Pharmacy (OSBP) and Jacklyn Cropper, for the purpose of resolving all issues between the parties relating to the OSBP investigation of Ms. Cropper covertly smuggling controlled substances into Trumbull Correctional Institution. Together, OSBP and Jacklyn Cropper are referred to hereinafter as “the parties.”

**JURISDICTION**

1. Pursuant to Section 4729.16 of the Ohio Revised Code and the rules adopted thereunder, the OSBP has the authority to suspend, revoke, or refuse to grant or renew any license issued pursuant to Section 4729.16 of the Ohio Revised Code to practice pharmacy as in intern in the state of Ohio.

2. Jacklyn Cropper is a licensed pharmacist under license number 03-3-24131.

**FACTS**

1. On or about November 24, 2015, the OSBP initiated an investigation of Jacklyn Cropper, pharmacist license number 03-3-24131, related to Jacklyn Cropper covertly smuggling controlled substances into Trumbull Correctional Institution.

2. On or about December 11, 2015, the OSBP sent a Notice of Opportunity for Hearing to Jacklyn Cropper, which outlined the allegations and provided notice of her right to a hearing, her rights in such hearing, and her right to submit contentions in writing.

3. On or about December 18, 2015, Jacklyn Cropper timely requested an administrative hearing, which was subsequently scheduled for January 10, 2017.

WHEREFORE, the parties desire to resolve the issues relating to the above-referenced findings without resorting to further administrative or judicial proceedings.

**TERMS**

NOW THEREFORE, in consideration of the mutual promises herein expressed, the parties knowingly and voluntarily agree as follows:

1. The recitals set forth above are incorporated in this Settlement Agreement as though fully set forth herein.
2. Jacklyn Cropper neither admits nor denies the allegations stated in the Notice of Opportunity for hearing letter dated December 11, 2015; however, the OSBP has evidence sufficient to sustain the allegations and hereby adjudicates the same. Further, the Board finds Violations of Law as set forth in 1(a), 1(b), 1(c), and (2)(c) of the Notice dated December 11, 2015; the Board hereby dismisses Violations of Law (2)(a), (2)(b), (2)(d), and (2)(e).

3. **JACKLYN CROPPER PERMANENTLY AND VOLUNTARILY SURRENDERS TO THE STATE BOARD OF PHARMACY HER LICENSE AND REGISTRATION TO PRACTICE PHARMACY, LICENSE NO. 03-3-24131, WITH DISCIPLINE PENDING.**

4. Jacklyn Cropper agrees to immediately return her license and wall certificate to the OSBP, if OSBP is not already in possession of both.

5. Jacklyn Cropper may never reapply for any license issued by the State of Ohio Board of Pharmacy pursuant to Chapters 3719., 3796., and 4729. of the Revised Code.

6. Jacklyn Cropper agrees to pay all reasonable costs associated with the collection of any payment, and of the prosecution of any violation of this Agreement.

7. Jacklyn Cropper understands that she has the right to be represented by counsel for review and execution of this agreement.

8. Jacklyn Cropper agrees and acknowledges that this OSBP disciplinary action must be disclosed to the proper licensing authority of any state or jurisdiction in which she currently holds a professional license.

9. Jacklyn Cropper specifically withdraws her request for a hearing in this matter and an opportunity to be heard pursuant to Chapter 119 of the Ohio Revised Code and waives her right to an appeal.

10. This Agreement may be executed in counterparts or facsimiles, each of which shall be deemed an original, but all of which shall constitute one and the same instrument.

11. All parties to this Agreement understand that this document is a public record pursuant to Ohio Revised Code Section 149.43.

12. This Agreement contains the entire agreement between the parties, there being no other agreement of any kind, verbal or otherwise, which varies the terms of this Agreement.

**R-2017-224** The Board received an application for the Continuing Education Provider Status of Weston Bush, RPh (03-1-22232) Sagamore Hills, Ohio. Ms. Yarosh moved that the Continuing Education Provider Status be approved. The motion was seconded by Mr. Weaver and approved by the Board: Aye-7.

**R-2017-225** The Board received an application for the Continuing Education Provider Status of Melissa Parson, RPh (03-2-34305) Centerville, Ohio. Mr. Weaver moved that the Continuing Education Provider Status be approved. The motion was seconded by Ms. Rudell and approved by the Board: Aye-7.
The Board received an application for the Continuing Education Provider Status of Christine Pfaff, RPh (03-3-25380) Lewis Center, Ohio. Mr. Cox moved that the Continuing Education Provider Status be approved. The motion was seconded by Mr. Wilt and approved by the Board: Aye-7.

Mr. Passafume moved that the Board adopt the following resolution:

Pursuant to rule 4729-5-11, the Board of Pharmacy is required to adopt a resolution providing the credential types or qualifications required for the responsible person of each classification of terminal and wholesale distributor of dangerous drugs license. Only individuals that meet the credentials specified may be the responsible person for that classification type.

Effective, September 1, 2016, the Board hereby adopts the following responsible person requirements:

<table>
<thead>
<tr>
<th>CL - CREDENTIAL CLASS</th>
<th>BUSINESS TYPE</th>
<th>BUSINESS TYPE DEFINITION</th>
<th>LIMITED OR UNLIMITED</th>
<th>RESP. PERSON</th>
<th>SPECIAL REQUIREMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>CL AS</td>
<td>Ambulatory Surgery</td>
<td>Unlimited</td>
<td>DO, MD, RPH, DDS, DPM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CL CI</td>
<td>Correctional Institution - clinic or med room that is located within a correctional facility or jail.</td>
<td>Unlimited</td>
<td>DO, MD, RPh, APRN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CL CL</td>
<td>Clinic - Health Dept., Free Clinic, Specialty Clinic</td>
<td>Unlimited</td>
<td>DO, MD, RPH, APRN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CL CTB</td>
<td>Chemical Treatment - METHADONE AND/OR BUPRENOPHINE</td>
<td>Unlimited</td>
<td>DO, MD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CL ED</td>
<td>Free Standing Emergency Department</td>
<td>Unlimited</td>
<td>DO, MD, RPH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CL FA</td>
<td>First Aid Room/Department</td>
<td>Limited</td>
<td>DO, MD, APRN</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Provide a notarized, signed Drug List, Personnel List & Protocols.
<table>
<thead>
<tr>
<th>CL</th>
<th>MC</th>
<th>Mobile Clinic - Drugs stored on truck, aircraft, bus, etc.; includes non-emergent helicopters and aircraft</th>
<th>Unlimited</th>
<th>DO, MD, DVM, APRN, DDS</th>
</tr>
</thead>
<tbody>
<tr>
<td>CL</td>
<td>MH</td>
<td>Mental Health</td>
<td>Unlimited</td>
<td>DO, MD</td>
</tr>
<tr>
<td>CL</td>
<td>ONC</td>
<td>Oncology Clinic</td>
<td>Unlimited</td>
<td>DO, MD, RPh</td>
</tr>
<tr>
<td>CL</td>
<td>PC</td>
<td>Prescriber Practice - general medical provider</td>
<td>Unlimited</td>
<td>DO, MD, APRN, DDS, OD, RPh</td>
</tr>
<tr>
<td>CL</td>
<td>POC</td>
<td>Point of Care - Pyxis located in another Hospital</td>
<td>Unlimited</td>
<td>RPH</td>
</tr>
<tr>
<td>CL</td>
<td>RT</td>
<td>Clinical Trials</td>
<td>Unlimited</td>
<td>DO, MD, DVM, OD, DDS</td>
</tr>
<tr>
<td>CL</td>
<td>SC</td>
<td>Sports Training Facility</td>
<td>Unlimited</td>
<td>DO, MD, APRN</td>
</tr>
<tr>
<td>CL</td>
<td>UR</td>
<td>Urgent Care + Convenience Care Clinic</td>
<td>Unlimited</td>
<td>DO, MD, APRN</td>
</tr>
<tr>
<td>STP</td>
<td>OTP</td>
<td>Opioid Treatment Facility</td>
<td>Unlimited</td>
<td>DO, MD</td>
</tr>
<tr>
<td>STP</td>
<td>PMC</td>
<td>Pain Management Clinic &amp; GPMC **GPMC was approved by the Medical and</td>
<td>Unlimited</td>
<td>DO, MD</td>
</tr>
<tr>
<td>FACILITY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------</td>
<td>-----------------</td>
<td>-----------------</td>
<td>-----------------</td>
<td></td>
</tr>
<tr>
<td>FACILITY</td>
<td>BUSINESS TYPE</td>
<td>BUSINESS TYPE DEFINITION</td>
<td>LIMITED OR UNLIMITED</td>
<td>RESP. PERSON</td>
</tr>
<tr>
<td>FCY</td>
<td>AC</td>
<td>Animal Control, Dog Pound, Dog Warden, Humane Society</td>
<td>Unlimited</td>
<td>DVM</td>
</tr>
<tr>
<td>FCY</td>
<td>AE</td>
<td>Animal Euthanasia</td>
<td>Limited</td>
<td>CET, DVM, DOG WARDEN</td>
</tr>
<tr>
<td>FCY</td>
<td>BB</td>
<td>Blood Bank</td>
<td>Unlimited</td>
<td>DO, MD</td>
</tr>
<tr>
<td>FCY</td>
<td>CC</td>
<td>Custodial Care, Pediatric Respite, Group Home</td>
<td>Unlimited</td>
<td>DO, MD</td>
</tr>
<tr>
<td>FCY</td>
<td>DG</td>
<td>Dog Trainer</td>
<td>Limited</td>
<td>MANAGEME NT + LENA</td>
</tr>
<tr>
<td>FCY</td>
<td>DU</td>
<td>Dialysis</td>
<td>Unlimited</td>
<td>DO, MD, APRN, RPH</td>
</tr>
<tr>
<td>FCY</td>
<td>EM</td>
<td>EMS Headquarters</td>
<td>Limited</td>
<td>DO, MD, RPH</td>
</tr>
</tbody>
</table>
| FCY | EMSS | EMS Satellite | Limited | DO, MD, RPH | Complete EMS Contact Addendum
|-----|------|--------------|---------|------------|--------------------------------------------------|
| FCY | HC   | Hospice - Patient is under comfort care only with 6 months or less to live. | Unlimited | DO, MD | Provide a notarized, signed Drug List, Personnel List & Protocols. Complete EMS Contact Addendum
| FCY | HH   | Home Health Care - providing services to the patient's homes or vaccination off-site | Limited | DO, MD | Provide a notarized, signed Drug List, Personnel List & Protocols.
| FCY | IC   | Infusion Center | Unlimited | DO, MD, RPH |
| FCY | IM   | Imaging | Limited | DO, MD | Provide a notarized, signed Drug List, Personnel List & Protocols.
| FCY | LA   | Laboratory/Research | Unlimited | DO, MD, PHD, CHEMIST, MANAGEMENT, RPH, DVM | Provide a proof of a degree in one of the following: chemistry, biochemistry, forensic science, biology, microbiology, or related pure applied
**Science. Proof of certified training in the field of expertise.**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>FCY</td>
<td>PD</td>
<td>Peritoneal Dialysis Center - ships directly to the patient’s home, no RPH performs the final verification</td>
<td>Limited</td>
<td>MANAGEME NT</td>
<td>Provide a notarized, signed Drug List, Personnel List &amp; Protocols.</td>
</tr>
<tr>
<td>FCY</td>
<td>PT</td>
<td>Physical Therapy</td>
<td>Limited</td>
<td>DO, MD</td>
<td>Provide a notarized, signed Drug List, Personnel List &amp; Protocols.</td>
</tr>
<tr>
<td>FCY</td>
<td>TE</td>
<td>Teaching Institution</td>
<td>Limited</td>
<td>DDS, DO, MD, HEAD OF PROGRAM (RN), RPh, APRN, PA, OD, DVM</td>
<td>Provide a notarized, signed Drug List, Personnel List &amp; Protocols. <strong>INJECTING INTO HUMANS RESP MUST BE A DDS, DO, MD, DPM, DDS, OD, RPH, or APRN</strong></td>
</tr>
<tr>
<td>FCY</td>
<td>VP</td>
<td>Veterinary Hospital or Zoo</td>
<td>Unlimited</td>
<td>DVM</td>
<td></td>
</tr>
<tr>
<td>FCY</td>
<td>VT</td>
<td>Veterinary Practice</td>
<td>Unlimited</td>
<td>DVM</td>
<td><em>FEE: $40.00, Cat. III ONLY</em></td>
</tr>
</tbody>
</table>

**MEDICAL GASES**
<table>
<thead>
<tr>
<th>MG - CREDENTIAL CLASS</th>
<th>BUSINESS TYPE</th>
<th>BUSINESS TYPE DEFINITION</th>
<th>LIMITED OR UNLIMITED</th>
<th>RESP. PERSON</th>
<th>SPECIAL REQUIREMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>MG</td>
<td>CM</td>
<td>Compressed Medical Gases (OXYGEN &amp; NITROUS OXIDE)</td>
<td>LIMITED</td>
<td>MD, DO, RN, APRN, LNHA, RRT, OD, DDS, DVM, RPH, MANAGEMENT</td>
<td>Provide a notarized, signed Drug List/Medical Gas Statement and an Authorized Personnel List. *Category II - ONLY</td>
</tr>
<tr>
<td>MG</td>
<td>CX</td>
<td>Contingency Stock (formerly ORCS)</td>
<td>LIMITED</td>
<td>RN, LNHA, MANAGEMENT, RRT</td>
<td>Provide a notarized, signed Drug List/Medical Gas Statement and an Authorized Personnel List. *Category II - ONLY</td>
</tr>
<tr>
<td>MG</td>
<td>GM</td>
<td>Manufacturer-Process Use + Food Processor</td>
<td>LIMITED</td>
<td>MANAGEMENT</td>
<td>Provide a notarized, signed Drug List/Medical Gas Statement and an Authorized Personnel List. *Category II - ONLY</td>
</tr>
<tr>
<td>MG</td>
<td>OX</td>
<td>Retail Seller or Biller of Oxygen (formerly RSOX and RBOX)</td>
<td>LIMITED</td>
<td>MD, DO, RN, APRN, LNHA, RRT, OD, DDS, DVM, RPH, MANAGEMENT</td>
<td>Provide a notarized, signed Drug List/Medical Gas Statement and an Authorized Personnel List. *Category II - ONLY</td>
</tr>
</tbody>
</table>

**PHARMACY**
<table>
<thead>
<tr>
<th>PMY - CREDENTIAL CLASS</th>
<th>BUSINESSTYPE</th>
<th>BUSINESS TYPE DEFINITION</th>
<th>LIMITED OR UNLIMITED</th>
<th>RESP. PERSON</th>
<th>SPECIAL REQUIREMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>PMY</td>
<td>CF</td>
<td>Central Fill Pharmacy</td>
<td>UNLIMITED</td>
<td>RPH</td>
<td></td>
</tr>
<tr>
<td>PMY</td>
<td>CH</td>
<td>Charitable Pharmacy</td>
<td>UNLIMITED</td>
<td>RPH</td>
<td>Must provide Tax Exempt Paperwork</td>
</tr>
<tr>
<td>PMY</td>
<td>CI</td>
<td>Correctional Institution</td>
<td>Unlimited</td>
<td>RPH</td>
<td></td>
</tr>
<tr>
<td>PMY</td>
<td>CP</td>
<td>Clinic Pharmacy</td>
<td>UNLIMITED</td>
<td>RPH</td>
<td></td>
</tr>
<tr>
<td>PMY</td>
<td>CR</td>
<td>Consulting Pharmacy - NO DRUGS ON SITE</td>
<td>LIMITED</td>
<td>RPH</td>
<td>*ONLY CAT II LICENSE</td>
</tr>
<tr>
<td>PMY</td>
<td>CRP</td>
<td>Consulting Pharmacy/Remote Order Entry ONLY - NO DRUGS ON SITE</td>
<td>LIMITED</td>
<td>RPH</td>
<td>*Only Cat II License</td>
</tr>
<tr>
<td>PMY</td>
<td>DM</td>
<td>Durable Medical Equipment</td>
<td>UNLIMITED</td>
<td>RPH</td>
<td></td>
</tr>
<tr>
<td>PMY</td>
<td>DR</td>
<td>Drug Repository</td>
<td>UNLIMITED</td>
<td>RPH</td>
<td>Must provide Tax Exempt Paperwork</td>
</tr>
<tr>
<td>PMY</td>
<td>FL</td>
<td>Fluid Therapy</td>
<td>UNLIMITED</td>
<td>RPH</td>
<td></td>
</tr>
<tr>
<td>PMY</td>
<td>HS</td>
<td>Hospital</td>
<td>UNLIMITED</td>
<td>RPH</td>
<td></td>
</tr>
<tr>
<td>PMY</td>
<td>II</td>
<td>Independent Community Retail Pharmacy - 1 Outlet</td>
<td>UNLIMITED</td>
<td>RPH</td>
<td></td>
</tr>
<tr>
<td>PMY</td>
<td>IL</td>
<td>Large Chain Retail Pharmacy - 12 or more Outlets</td>
<td>UNLIMITED</td>
<td>RPH</td>
<td></td>
</tr>
<tr>
<td>PMY</td>
<td>IP</td>
<td>Pharmacy Servicing Institutions</td>
<td>UNLIMITED</td>
<td>RPH</td>
<td>*May included Mental Health Pharmacies &amp; Nursing Home Inpatient Pharmacies</td>
</tr>
<tr>
<td>PMY</td>
<td>IS</td>
<td>Small Chain Retail Pharmacy - 2 to 11 Outlets</td>
<td>UNLIMITED</td>
<td>RPH</td>
<td></td>
</tr>
<tr>
<td>PMY</td>
<td>KIOSK</td>
<td>Kiosk</td>
<td>UNLIMITED</td>
<td>RPH</td>
<td>*Must have Board approval</td>
</tr>
<tr>
<td>-----</td>
<td>-------</td>
<td>-------</td>
<td>-----------</td>
<td>-----</td>
<td>--------------------------</td>
</tr>
<tr>
<td>PMY</td>
<td>MD</td>
<td>Multi-Disciplinary</td>
<td>UNLIMITED</td>
<td>RPH</td>
<td>**MAY INCLUDE COMPOUNDING</td>
</tr>
<tr>
<td>PMY</td>
<td>MO</td>
<td>Mail Order</td>
<td>UNLIMITED</td>
<td>RPH</td>
<td></td>
</tr>
<tr>
<td>PMY</td>
<td>MTM</td>
<td>Medication Therapy Management - NO DRUGS ON SITE</td>
<td>LIMITED</td>
<td>RPH</td>
<td></td>
</tr>
<tr>
<td>PMY</td>
<td>NU</td>
<td>Nuclear Pharmacy</td>
<td>UNLIMITED</td>
<td>RPH</td>
<td></td>
</tr>
<tr>
<td>PMY</td>
<td>ONC</td>
<td>Oncology Pharmacy</td>
<td>UNLIMITED</td>
<td>RPH</td>
<td></td>
</tr>
<tr>
<td>PMY</td>
<td>SP</td>
<td>Specialty Pharmacy - High $ Drugs</td>
<td>UNLIMITED</td>
<td>RPH</td>
<td>**MAY INCLUDE COMPOUNDING</td>
</tr>
</tbody>
</table>

**PHARMACY SUPPLIED CONTIGENCY STOCK**

<table>
<thead>
<tr>
<th>PSCS - CREDENTIALAL CLASS</th>
<th>BUSINESS TYPE</th>
<th>BUSINESS TYPE DEFINITION</th>
<th>LIMITED OR UNLIMITED</th>
<th>RESP. PERSON</th>
<th>SPECIAL REQUIREMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSCS</td>
<td>CC</td>
<td>Contingency stock within custodial care</td>
<td>Unlimited</td>
<td>RPH</td>
<td></td>
</tr>
<tr>
<td>PSCS</td>
<td>CI</td>
<td>Contingency stock within a Correctional Institution</td>
<td>UNLIMITED</td>
<td>RPH</td>
<td></td>
</tr>
<tr>
<td>PSCS</td>
<td>CS</td>
<td>Contingency stock within a Community Pharmacy</td>
<td>UNLIMITED</td>
<td>RPH</td>
<td></td>
</tr>
<tr>
<td>PSCS</td>
<td>HC</td>
<td>Contingency stock within a Hospice Facility</td>
<td>UNLIMITED</td>
<td>RPH</td>
<td></td>
</tr>
<tr>
<td>PSCS</td>
<td>HS</td>
<td>Contingency stock within a Hospital</td>
<td>UNLIMITED</td>
<td>RPH</td>
<td></td>
</tr>
<tr>
<td>PSCS</td>
<td>MH</td>
<td>Contingency stock within a Mental Health Institution</td>
<td>UNLIMITED</td>
<td>RPH</td>
<td></td>
</tr>
<tr>
<td>PSCS</td>
<td>NH</td>
<td>Contingency stock within a Nursing Home</td>
<td>UNLIMITED</td>
<td>RPH</td>
<td></td>
</tr>
<tr>
<td>------</td>
<td>----</td>
<td>----------------------------------------</td>
<td>-----------</td>
<td>-----</td>
<td></td>
</tr>
</tbody>
</table>

**NON-RESIDENT PHARMACY**

<table>
<thead>
<tr>
<th>NRP - CREDENTIAL CLASS</th>
<th>BUSINESS TYPE</th>
<th>BUSINESS TYPE DEFINITION</th>
<th>LIMITED OR UNLIMITED</th>
<th>RESP. PERSON</th>
<th>SPECIAL REQUIREMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>NRP</td>
<td>CF</td>
<td>Non-Resident Central Fill Pharmacy</td>
<td>UNLIMITED</td>
<td>RPH</td>
<td></td>
</tr>
<tr>
<td>NRP</td>
<td>CR</td>
<td>Non-Resident Consulting Pharmacy - no drugs onsite</td>
<td>LIMITED</td>
<td>RPH</td>
<td></td>
</tr>
<tr>
<td>NRP</td>
<td>CRP</td>
<td>Remote Order Entry ONLY - NO DRUGS ON SITE</td>
<td>LIMITED</td>
<td>RPH</td>
<td>*Only Cat II License</td>
</tr>
<tr>
<td>NRP</td>
<td>IP</td>
<td>Non-Resident Pharmacy Servicing an Institution</td>
<td>UNLIMITED</td>
<td>RPH</td>
<td></td>
</tr>
<tr>
<td>NRP</td>
<td>MO</td>
<td>Non-Resident Mail Order Pharmacy</td>
<td>UNLIMITED</td>
<td>RPH</td>
<td></td>
</tr>
<tr>
<td>NRP</td>
<td>MTM</td>
<td>Non-Resident Medication Therapy Management - NO DRUGS ON SITE</td>
<td>LIMITED</td>
<td>RPH</td>
<td>*Only Cat II License</td>
</tr>
<tr>
<td>NRP</td>
<td>NU</td>
<td>Non-Resident Nuclear Pharmacy</td>
<td>UNLIMITED</td>
<td>RPH</td>
<td></td>
</tr>
<tr>
<td>NRP</td>
<td>SP</td>
<td>Non-Resident Specialty Pharmacy - High $ Drugs</td>
<td>UNLIMITED</td>
<td>RPH</td>
<td><strong>MAY INCLUDE COMPOUNDING</strong></td>
</tr>
</tbody>
</table>

**WHOLESALER**

<table>
<thead>
<tr>
<th>WHS - WHOLESALER / MANUFACTURER CREDENTIAL CLASS</th>
<th>BUSINESS TYPE</th>
<th>BUSINESS TYPE DESCRIPTION</th>
<th>RESP. PERSON</th>
<th>SPECIAL REQUIREMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>WHS</td>
<td>BC</td>
<td>Bulk Pharmaceutical Chemical Seller</td>
<td>MANAGEMENT</td>
<td></td>
</tr>
<tr>
<td>WHS</td>
<td>BG</td>
<td>Buying Group - A group of Wholesalers/Sto</td>
<td>MANAGEMENT</td>
<td></td>
</tr>
<tr>
<td>WHS</td>
<td>CM</td>
<td>Compressed Medical Gases</td>
<td>MANAGEME NT</td>
<td></td>
</tr>
<tr>
<td>------</td>
<td>-----</td>
<td>---------------------------</td>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td>WHS</td>
<td>CN</td>
<td>Clinic Wholesaler: Blood Banks, Health Departments</td>
<td>MANAGEME NT</td>
<td></td>
</tr>
<tr>
<td>WHS</td>
<td>DM</td>
<td>Durable Medical Equipment</td>
<td>Respiratory Care Board license if applicable (ORC 4752)</td>
<td></td>
</tr>
<tr>
<td>WHS</td>
<td>FS</td>
<td>Full Service</td>
<td>MANAGEME NT</td>
<td></td>
</tr>
<tr>
<td>WHS</td>
<td>IE</td>
<td>Import/Export - importing drugs from in/out of the country</td>
<td>MANAGEME NT</td>
<td></td>
</tr>
<tr>
<td>WHS</td>
<td>IR</td>
<td>In-State Rx Disposal</td>
<td>Must provide DEA &amp; EPA registration</td>
<td></td>
</tr>
<tr>
<td>WHS</td>
<td>LA</td>
<td>Lab</td>
<td>MANAGEME NT</td>
<td></td>
</tr>
<tr>
<td>WHS</td>
<td>MF</td>
<td>Full Service Manufacturer</td>
<td>If manufacturing Kits- need FDA registration</td>
<td></td>
</tr>
<tr>
<td>WHS</td>
<td>OD</td>
<td>Out-of-State Rx Disposal</td>
<td>Must provide DEA &amp; EPA registration</td>
<td></td>
</tr>
<tr>
<td>WHS</td>
<td>PM</td>
<td>Pre-Packaged Meds</td>
<td>FDA repackaging registration</td>
<td></td>
</tr>
<tr>
<td>WHS</td>
<td>PU</td>
<td>Public Health Preparedness</td>
<td>MANAGEME NT</td>
<td></td>
</tr>
<tr>
<td>WHS</td>
<td>RE</td>
<td>Re-packed Meds</td>
<td>FDA repackaging registration</td>
<td></td>
</tr>
<tr>
<td>WHS</td>
<td>WD</td>
<td>Waste Disposal</td>
<td>MANAGEME NT</td>
<td></td>
</tr>
<tr>
<td>CREDENTIAL CLASS</td>
<td>BUSINESS TYPE</td>
<td>BUSINESS TYPE DESCRIPTION</td>
<td>RESP. PERSON</td>
<td>SPECIAL REQUIREMENTS</td>
</tr>
<tr>
<td>------------------</td>
<td>--------------</td>
<td>---------------------------</td>
<td>--------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>WHS</td>
<td>WCSM</td>
<td>Controlled Substance Manufacturer</td>
<td>MANAGEMEN</td>
<td>T</td>
</tr>
<tr>
<td>WHS</td>
<td>WCSW</td>
<td>Controlled Substance Wholesaler</td>
<td>MANAGEMEN</td>
<td>T</td>
</tr>
<tr>
<td>WHS</td>
<td>WI</td>
<td>Within own Corporation</td>
<td>MANAGEMEN</td>
<td>T</td>
</tr>
<tr>
<td>WDIS - THIRD PARTY LOGISTICS CREDENTIAL CLASS</td>
<td>BUSINESS TYPE</td>
<td>BUSINESS TYPE DESCRIPTION</td>
<td>RESP. PERSON</td>
<td>SPECIAL REQUIREMENTS</td>
</tr>
<tr>
<td>WDIS</td>
<td>3PL</td>
<td>3PL'S- Stores drug onsite but does not have ownership of the drug</td>
<td>MANAGEMEN</td>
<td>T</td>
</tr>
<tr>
<td>WDIS</td>
<td>WCSV</td>
<td>Controlled Substance Wholesaler</td>
<td>MANAGEMEN</td>
<td>T</td>
</tr>
<tr>
<td>WVMF - VIRTUAL MANUFACTURER CREDENTIAL CLASS</td>
<td>BUSINESS TYPE</td>
<td>BUSINESS TYPE DESCRIPTION</td>
<td>RESP. PERSON</td>
<td>SPECIAL REQUIREMENTS</td>
</tr>
<tr>
<td>WVMF</td>
<td>VM</td>
<td>Virtual Manufacturer - NO DRUGS ON SITE</td>
<td>MANAGEMEN</td>
<td>Must provide a state license or VAWD accreditation</td>
</tr>
<tr>
<td>WVMF</td>
<td>WCSV</td>
<td>Controlled Substance Manufacturer</td>
<td>MANAGEMEN</td>
<td>T</td>
</tr>
<tr>
<td>WMOF - OUTSOURCER CREDENTIAL CLASS</td>
<td>BUSINESS TYPE</td>
<td>BUSINESS TYPE DESCRIPTION</td>
<td>RESP. PERSON</td>
<td>SPECIAL REQUIREMENTS</td>
</tr>
<tr>
<td>WMOF</td>
<td>FS</td>
<td>Full Service</td>
<td>Pharmacist</td>
<td>Must provide the FDA inspection report (including any 483A) and a State Inspection less than 2 years’ old</td>
</tr>
<tr>
<td>WMOF</td>
<td>SCY</td>
<td>Sterile Compounding</td>
<td>Pharmacist</td>
<td>T</td>
</tr>
</tbody>
</table>
The motion was seconded by Ms. Yarosh and approved by the Board: Aye-7.

**R-2017-228** Ms. Yarosh moved that the Board’s Responsible Person Committee handle all future Multiple RP Requests and will only come before the full Board if the committee cannot make a determination. The motion was seconded by Mr. Passafume and approved by the Board: Aye-7.

**R-2017-229** Ms. Yarosh moved to adopt the following Multiple RP Request decisions presented by the Responsible Person Committee:

- **Amy Myers, RPh (03-1-20444)-Denied**
  - Riley Creek Pharmacy: Pandora, Ohio (02-2023650)
  - Pharmacy Solutions: Pandora, Ohio (02-2023900)

- **Nicolas Beatty, RPh (03-1-35569)-Approved**
  - Fayette Pharmacy: Washington Courthouse, Ohio (02-1877800)
  - Fayette County Health Department: Washington Courthouse, Ohio (02-1444800)

- **Helen Betizel, RPh (03-2-18049)-Approved**
  - Eden Springs Pharmacy: Green Springs, Ohio (02-2653250)
  - Eden Springs Pharmacy: Green Springs, Ohio (02-2653300)

- **Emily Hoskins, RPh (03-3-34818)-Approved**
  - Arrow Springs Outpatient: Lebanon, Ohio (02-2091050)
  - Arrow Springs Pharmacy: Lebanon, Ohio (02-2667050)

- **Michael Schumate, RPh (03-1-12280)-Approved**
  - Grace Hospital Pharmacy: Cleveland, Ohio (02-1337950)
  - Access RX Pharmacy, LLC: Dayton, Ohio (02-2667050)

- **Robert Castro, RPh (Out of State)-Approved**
  - Zo Skin Health, Inc.: Irvine, California (01-2274100)
  - Zo Skin Health, Inc.: Irvine, California (01-2647500)

- **Michael Turnamian, RPh (Out of State)-Approved**
  - Gemini Laboratories, LLC: Bridgewater, New Jersey (01-2402350)
  - Solis Generic Pharmaceuticals, LLC: Bridgewater, New Jersey (01-2647300)

- **Harold Deas, RPh (Out of State)-Approved**
  - Acela Pharmaceuticals, LLC: Alpharetta, Georgia (01-1847900)
  - Avion Pharmaceuticals, LLC: Alpharetta, Georgia (01-2181900)

- **Vincent Durante, RPh (Out of State)-Approved**
  - Pharma-C, Inc.: Paramus, New Jersey (01-2157400)
• World Gen, LLC: Paramus, New Jersey (01-1406600)
• WG Critical Care, LLC: Paramus, New Jersey (01-1958750)
• Interchem Corporation: Paramus, New Jersey (01-1715550)

- Jacob Beck, RPh (Out of State)-Approved
  - AnovoRX Distributions, LLC: Memphis, Tennessee (01-2348100)
  - AnovoRX Distributions, LLC: Memphis, Tennessee (01-2617500)

- Robert Justman (Out of State)-Approved
  - Galderma Laboratories: Fort Worth, Texas (01-1217800)
  - Owen Laboratory: Fort Worth, Texas (01-2498350)

The motion was seconded by Mr. Passafume and approved by the Board: Aye-7.

R-2017-230 The Board received a request for an approval to Ohio Administrative Code Rule 4729-5-11 (A)(1) requesting that Jon Myers, RPh (03-1-22750) Hicksville, Ohio be the Responsible Person for the following pharmacies:

- Hicksville Pharmacy: Hicksville, Ohio (02-2091020)
- Community Memorial Hospital: Hicksville, Ohio (02-2023900)

After discussion, Ms. Yarosh moved that the Board approve the request for a period of 6 months and must petition for an extension if one is required. The motion was seconded by Ms. Marchal and approved by the Board: Aye-7.

R-2017-231 The Board received a request for an approval to Ohio Administrative Code Rule 4729-5-11 (A)(1) requesting that Dwight Mosley, MD (35.092811) New Albany, Ohio, be the Responsible Person for the following Pain Management Clinics:

- Comprehensive Pain Specialists: Columbus, Ohio (02-2450800)
- Comprehensive Pain Specialists: Cincinnati, Ohio (02-2450750)

After discussion, Mr. Passafume moved that the Board approve the request for a period of 90 days. The motion was seconded by Mr. Cox and approved by the Board: Aye-7.

R-2017-232 The Board received an extension request for storage of records of Meijer Pharmacy, Walgreens Pharmacy, and CVS Pharmacy pursuant to Rule 4729-9-11. Mr. Weaver moved that the specific requests be approved. The motion was seconded by Ms. Marchal and approved by the Board: Aye-7.

R-2017-233 The Board received a CQE request of Camela Walker. Ms. Yarosh moved that the CQE request be approved. The motion was seconded by Mr. Weaver and approved by the Board: Aye-5/Deny-2.

1:47 p.m. Ms. Witt, Human Resources Manager, introduced new Board employees Lori Klopp and Paula Economu.

1:50 p.m. Mark Pilkington and Tony Matessa, Cardinal Health, gave a presentation to the Board regarding the InPower Personal Medication Assistant.
2:50 p.m. The presentation ended.

The Board recessed briefly

3:00 p.m. The meeting reconvened in Room South B&C.

The Board was joined by Assistant Attorney General Steven Kochheiser to create a record in accordance with the Ohio Revised Code Chapters 119. and 4729. in the matter of Inverness Vet Hospital, Toledo, Ohio.

3:12 p.m. The hearing ended and the record was closed.

Ms. Marchal moved that the Board recess in order to consider the quasi-judicial matter in accordance with Chapter 119. of the Revised Code and the case precedent of Angerman v. State Medical Bd. (1990) 70 Ohio App.3d 346 and TBC Westlake Inc. v. Hamilton Cty Bd of Revision, et al. (1998) 81 Ohio St.3d 58. The motion was seconded by Ms. Rudell and a roll-call vote was conducted by President Moné as follows: Cox-yes; Marchal-yes; Passafume-yes; Rudell-yes; Weaver-yes; Wilt-yes and Yarosh-yes.

4:06 p.m. The recess ended and the hearing was opened to the public.

R-2017-234 After votes were taken in public session, the Board adopted the following order in the matter of Inverness Vet Hospital, Toledo, Ohio.

ORDER OF THE STATE BOARD OF PHARMACY
(Case Number 2015-2234)

In The Matter Of:

Inverness Veterinary Hospital

c/o Jack Niggemeyer, DVM

4425 Hill Ave

Toledo, Ohio 43615

(TDDD License No. 02-2563200)

INTRODUCTION

The Matter of Inverness Veterinary Hospital came for consideration on January 9, 2017, before the following members of the State of Ohio Board of Pharmacy (Board): Michael A. Moné, R.Ph., Presiding; Joshua M. Cox, R.Ph; Megan E. Marchal, R.Ph.; Curtis L. Passafume, Jr., R.Ph.; Jennifer M. Rudell, R.Ph.; Fred M. Weaver, R.Ph.; Shawn C. Wilt, R.Ph. and Kilee S. Yarosh, R.Ph.

Inverness Veterinary Hospital was not present nor represented by Counsel. The State of Ohio was represented by Steven Kochheiser, Assistant Attorney General.
SUMMARY OF EVIDENCE

State’s Witnesses:
1. Homer Chapa—State of Ohio Board of Pharmacy

Respondent’s Witnesses:
None

State’s Exhibits:
1. Notice of Opportunity for Hearing/Proposal to Deny Application 07-05-2016
2. Credential View Screen 11-21-2016
3. Terminal Distributor of Dangerous Drugs Application 10-28-2015
4. Records from Ohio Veterinary Medical Licensing Board 03-19-2007
5. Handwritten Statement No Date

Respondent’s Exhibits:
None

FINDINGS OF FACT

After having heard the testimony, observed the demeanor of the witnesses, considered the evidence, and weighed the credibility of each, the Board finds the following to be fact:

1. On or about October 28, 2015, the Board received an application for a Terminal Distributor of Dangerous Drugs license from Inverness Veterinary Hospital by and through Jack Niggemyer who did sign and submit the document with an answer of “No” to the question inquiring whether the applicant, owner(s), Responsible Person, any agent or any employee of the location being licensed, or any officer of the corporation, ever been the subject of disciplinary action (or pending action) by any state or federal agency; even if subsequently dismissed or resolved without formal discipline. Upon further investigation, it was determined that answer was false.

2. During an investigation, an Agent of the Board discovered that Jack Niggemyer, Responsible Person for Inverness Veterinary Hospital, was disciplined by the State of Ohio Veterinary Board.

a. On or about March 14, 2007, Jack Niggemyer entered into a settlement agreement with the Ohio Veterinary Board for failing to keep medical records in accordance with Ohio veterinary practice act as set forth in Section 4741 of the ORC and Chapter 4741 of the Ohio Administrative Code (OAC). Pursuant to the settlement agreement, Jack Niggemyer received a letter of reprimand, was required to pay a $500 fine, and submit ten (10) patient records each quarter to the Ohio Veterinary Board office.

CONCLUSIONS OF LAW

1. Such conduct as set forth in the Findings of Fact Section also constitutes a violation of the following division of Section 4729.57 of the ORC:
a. Making any false material statements in an application for a license as a TDDD, ORC Section 4729.57(A)(1).

2. Finally, such conduct as set forth in paragraphs (1) and (2) of the Findings of Fact Section constitutes the following violation of the OAC, each punishable by a maximum fine of $1,000:

   a. Has been disciplined by any professional licensing board, OAC Rule 4729-9-19(A)(7).

DECISION OF THE BOARD

1. Pursuant to Section 4729.57 of the Ohio Revised Code, the State of Ohio Board of Pharmacy hereby imposes a monetary penalty in the amount of $1,150.00, by means of a cashier’s check made payable to “Treasurer, State of Ohio,” mailed with the enclosed form to the OSBP, 77 South High Street, 17th Floor, Columbus, Ohio 43215-6126, no later than 30 days from the effective date of this Order.

2. Pursuant to Sections 4729.57, 4729.54 and 4729.55 of the Ohio Revised Code, and after consideration of the record as a whole, upon receipt of payment of the monetary penalty the State of Ohio Board of Pharmacy approves the Application for Registration as a Terminal Distributor of Dangerous Drugs submitted by Inverness Veterinary Hospital on or about October 28, 2015.

Mr. Wilt moved for Findings of Fact; Mr. Weaver seconded the motion. Motion passed (Aye-7/Nay-0).

Ms. Marchal moved for Conclusions of Law; Mr. Wilt seconded the motion. Motion passed (Aye-7/Nay-0).

Ms. Marchal moved for Action of the Board; Mr. Weaver seconded the motion. Motion passed (Aye-7/Nay-0).

SO ORDERED.

R-2017-235 Mr. Moné announced that the citation issued to LoneStar Pharmaceuticals, Argyle, Texas is hereby dismissed.

R-2017-236 Mr. Moné announced that the citation issued to Turing Pharmaceuticals, New York, New York is hereby dismissed.

4:10 p.m. The Board was joined by Assistant Attorney General Steven Kochheiser to create a record in accordance with the Ohio Revised Code Chapters 119. and 4729. in the matter of AlexRon Pharmaceuticals, LLC, Willoughby, Ohio.

5:02 p.m. The hearing ended and the record was closed.

Mr. Weaver moved that the Board recess in order to consider the quasi-judicial matter in accordance with Chapter 119. of the Revised Code and the case precedent of Angerman v. State Medical Bd. (1990) 70 Ohio App.3d 346 and TBC Westlake Inc. v. Hamilton Cty Bd of
Revision, et al. (1998) 81 Ohio St.3d 58. The motion was seconded by Ms. Yarosh and a roll-call vote was conducted by President Moné as follows: Marchal-yes; Passafume-yes; Rudell-yes; Weaver-yes; Wilt-yes and Yarosh-yes.

5:26 p.m. The recess ended and the hearing was opened to the public.

R-2017-237 After votes were taken in public session, the Board adopted the following order in the matter of AlexRon Pharmaceuticals, LLC, Willoughby, Ohio.

ORDER OF THE STATE BOARD OF PHARMACY
(Case Number 2016-1849)

In The Matter Of:

AlexRon Pharmaceuticals, LLC
c/o Ronald Russo
4834 Wood Street
Willoughby, Ohio 44094
(DENIED License No. 01-2636800)

INTRODUCTION


Joshua M. Cox, R.Ph.; Absent.

AlexRon Pharmaceuticals, LLC was not present nor represented by Counsel. The State of Ohio was represented by Steven Kochheiser, Assistant Attorney General.

SUMMARY OF EVIDENCE

State’s Witnesses:
1. Trey Edwards—State of Ohio Board of Pharmacy

Respondent’s Witnesses:

None

State’s Exhibits:
1. Notice of Opportunity for Hearing/Proposal to Deny Application 10-11-2016
2. Request for Hearing 11-02-2016
3. Notice of Hearing Date for December Board Meeting 11-04-2016
5. Wholesale Distributor of Dangerous Drugs Application 12-03-2015
6. Wholesale Distributor of Dangerous Drugs Application 03-10-2016
<table>
<thead>
<tr>
<th></th>
<th>Event Description</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.</td>
<td>Request to Withdraw Application(s)</td>
<td>04-14-2016</td>
</tr>
<tr>
<td>8.</td>
<td>Wholesale Distributor of Dangerous Drugs Application</td>
<td>06-30-2016</td>
</tr>
<tr>
<td>9.</td>
<td>Email Correspondence regarding Counsel Status</td>
<td>07-28-2016</td>
</tr>
<tr>
<td>10.</td>
<td>Certificate from Ohio Supreme Court</td>
<td>11-21-2016</td>
</tr>
<tr>
<td>11.</td>
<td>Investigative Photos</td>
<td>No Date</td>
</tr>
<tr>
<td>12.</td>
<td>Notice of Hearing Date for January Board Meeting</td>
<td>12-07-2016</td>
</tr>
</tbody>
</table>

**Respondent's Exhibits:**

None

**FINDINGS OF FACT & CONCLUSIONS OF LAW**

After having heard the testimony, observed the demeanor of the witnesses, considered the evidence, and weighed the credibility of each, the Board finds the following to be fact:

1. The Board received an application for a Wholesale Distributor of Dangerous Drugs license from Alexron Pharmaceuticals, Inc. dated on or about June 30, 2016 signed by Ronald Russo. In its review of the application, the Board determined that you do not meet the minimum qualifications for registration as a wholesaler distributor of dangerous drugs.

2. During an investigation by an agent of the Board, it was also discovered that Responsible Person, Ronald Russo, is not a licensed attorney authorized to practice law in the state of Ohio. On the application and related documents submitted to the board, Ronald Russo held himself out as being authorized and capable of practicing law in this state by signing as General Counsel for Alexron Pharmaceutical, LLC and by indicating he is “a business attorney with twenty (20) years experience.” The Lake County Bar Association has opened an unauthorized practice of law investigation on Mr. Russo as a result of his representations that he is a licensed attorney.

3. The applicant’s past experience in the manufacture or distribution of dangerous drugs, including controlled substances, is not acceptable to the board, in violation of Section 4729.53(A)(2) of the Revised Code and Rule 4729-9-28(H) of the Administrative Code; and

4. The applicant is not equipped as to land, buildings, equipment, and personnel to properly carry on the business of a wholesale distributor of dangerous drugs, including providing adequate security for and proper storage conditions and handling for dangerous drugs, and is not complying with the requirements under this chapter and the rules adopted pursuant thereto for maintaining and making available records to properly identified board officials and federal, state, and local law enforcement agencies, in violation of Sections 3719.03(B) and 4729.53(A)(3) of the Revised Code; and

5. The applicant has not furnished satisfactory proof that personnel employed by the applicant have the appropriate education or experience, as determined by the board, to assume responsibility for positions related to compliance with this chapter and the rules adopted pursuant thereto, in violation of Section 4729.53(A)(4) of the Revised Code; and
6. Adequate safeguards are not assured to prevent the sale of dangerous drugs to any person other than those named in division (B) of Section 4729.51 of the Revised Code, in violation of Section 4729.53(A)(6) of the Revised Code.

7. Kathleen Russo is named as an authorized member, manager, or representative of AlexRon Pharmaceutical, LLC in the Articles of Organization dated on or about July 24, 2012 with the Ohio Secretary of State’s office; however, Kathleen Russo is not listed on the application materials nor has she provided fingerprints for a criminal background check in violation of Rule 4729-9-16 of the Ohio Administrative Code.

8. The granting of the registration certificate is not in the public interest, in accordance with Sections 4729.53(B) and 3719.03(E) of the Revised Code.

9. The applicant’s policies and procedures fail to meet minimum standards, in violation of Rules 4729-9-28(F) and 4729-9-28(G)

10. Additionally, Ronald Russo made material misrepresentations as to his status as a licensed attorney and the Board finds he is not of good moral character in violation of Section 3719.03(A) of the Revised Code and Rule 4729-9-19(A)(4) of the Ohio Administrative Code.

**DECISION OF THE BOARD**

1. Pursuant to Section 4729.56 of the Ohio Revised Code, Rule 4729-9-19 of the Ohio Administrative Code, and after consideration of the record as a whole, the State of Ohio Board of Pharmacy hereby denies the Application for Registration as a Wholesale Distributor of Dangerous Drugs submitted by AlexRon Pharmaceuticals, LLC on or about June 30, 2016.

2. Pursuant to Chapter 4729-9-01(I) of the Ohio Administrative Code, AlexRon Pharmaceuticals, LLC may not reapply for any State of Ohio Board of Pharmacy license for a minimum of three years.

3. Pursuant to Section 4729.56 of the Ohio Revised Code, the State of Ohio Board of Pharmacy imposes a monetary penalty in the amount of $1,000.00, by means of a cashier’s check made payable to “Treasurer, State of Ohio,” mailed with the enclosed form to the OSBP, 77 South High Street, 17th Floor, Columbus, Ohio 43215-6126, no later than 30 days from the effective date of this Order.

Mr. Passafume moved for Findings of Fact; Mr. Weaver seconded the motion. Motion passed (Aye-6/Nay-0).

Ms. Yarosh moved for Action of the Board; Mr. Wilt seconded the motion. Motion passed (Aye-6/Nay-0).

SO ORDERED.

5:31 p.m. Mr. McNamee led a discussion regarding Rule 4729-5-14.
Mr. Passafume moved that Rule 4729-5-14 be approved for filing with CSI and JCARR. The motion was seconded by Mr. Wilt and approved by the Board: Aye-6.

5:49 p.m. Mr. McNamee led a discussion regarding Rules 4729-29-03, 4729-29-02, and 4729-29-01.

Mr. Passafume moved that Rules 4729-29-03, 4729-29-02, and 4729-29-01 be approved for filing with JCARR. The motion was seconded by Ms. Rudell and approved by the Board: Aye-6.

6:37 p.m. The Board recessed for the day.

---

Tuesday, January 10, 2017

8:36 a.m. The Ohio State Board of Pharmacy convened in Room South B&C, 31st Floor, of the Vern Riffe Center for Government and the Arts, 77 South High Street, Columbus, Ohio, with the following members present:

Michael A. Moné, RPh, President; Megan E. Marchal, RPh; Curtis L. Passafume, Jr., RPh; Jennifer M. Rudell, RPh; Fred M. Weaver, RPh; Shawn C. Wilt, RPh and Kilee S. Yarosh, RPh

Ms. Marchal moved that the Board go into Executive Session to consider the investigation of charges or complaints against a licensee, confer with Board counsel regarding a pending or imminent court action and to discuss matters required to be confidential by law pursuant to Section 121.22(G)(1), (3) & (5) of the Ohio Revised Code. The motion was seconded by Mr. Passafume and a roll-call vote was conducted by President Moné as follows: Marchal-yes; Rudell-yes; Weaver-yes; Wilt-yes and Yarosh-yes.

9:17 a.m. The meeting reconvened in Room South B&C.

The Board was joined by Assistant Attorney General Steven Kochheiser to create a record in accordance with the Ohio Revised Code Chapters 119. and 4729. in the matter of Toxicology Associates, Inc., Columbus, Ohio.

10:15 a.m. The hearing ended and the record was closed.

Ms. Marchal moved that the Board recess in order to consider the quasi-judicial matter in accordance with Chapter 119. of the Revised Code and the case precedent of Angerman v. State Medical Bd. (1990) 70 Ohio App.3d 346 and TBC Westlake Inc. v. Hamilton Cty Bd of Revision, et al. (1998) 81 Ohio St.3d 58. The motion was seconded by Ms. Rudell and a roll-call vote was conducted by President Moné as follows: Marchal-yes; Passafume-yes; Rudell-yes; Weaver-yes; Wilt-yes and Yarosh-yes.

10:30 a.m. The recess ended and the hearing was opened to the public.

R-2017-240 After votes were taken in public session, the Board adopted the following order in the matter of Toxicology Associates, Inc., Columbus, Ohio.
ORDER OF THE STATE OF OHIO BOARD OF PHARMACY
(Case Number 2016-1519)

In The Matter Of:

Toxicology Associates, Inc.
999 Bethel Road
Columbus, Ohio 43214
TDDD No. 02-0076050

INTRODUCTION


Joshua M. Cox, R.Ph; Absent.

Toxicology Associates, Inc. was not present nor represented by Counsel. The State of Ohio was represented by Steven Kochheiser, Assistant Attorney General.

SUMMARY OF EVIDENCE

State’s Witnesses:
1. Paul Schad, RPh—State of Ohio Board of Pharmacy
2. Erin Reed, Esq.—State of Ohio Board of Pharmacy

Respondent’s Witnesses:
None

State’s Exhibits:
1. Notice of Opportunity for Hearing 11-29-2016
2. Credential View Screen 01-03-2017
3. Complaint from Margaret A. Walter MD FACS 05-15-2016
5. Inspection Report 06-17-2014
6. Response to June 17, 2014 Inspection Report 06-17-2014
8. Photos from October 3, 2016 Inspection 10-03-2016

Respondent’s Exhibits:
None
FINDINGS OF FACT

After having heard the testimony, observed the demeanor of the witnesses, considered the evidence, and weighed the credibility of each, the Board finds the following to be fact:

1. On or about May 16, 2016, the Board received a complaint concerning Toxicology Associates, Inc.’s practices as a laboratory with a terminal distributor of dangerous drugs license.

2. The State of Ohio Board of Pharmacy staff conducted inspections at your facility in October of 2016 and observed the following; similar observations were also noted during an inspection conducted in June of 2014:

   a. The poor condition of the facility, its equipment, and cleanliness. Specifically, filthy counter-tops, floors and ceiling tiles. The filthy counter-tops stored unmarked containers and beakers with various chemicals. The noxious fumes emanating from the containers and beakers were not properly ventilated out of the facility because the three fume hoods, covered in dirt or rust, were not in working order and/or were not operational. Several chemicals on the work benches were expired. In addition, old food contained in a freezer without a thermometer as well as expired chemicals were found within the facility.

   b. Employees have unsupervised access to controlled substances, which are stored in an unlocked refrigerator and not in a substantially constructed cabinet.

   c. No records of controlled substances inventory.

   d. Expired controlled substances used for analysis.

3. The Compliance and Enforcement Staff that conducted the inspection ended the inspection early due to health and safety concerns of the noxious fumes and lack of ventilation within the facility.

CONCLUSIONS OF LAW

1. Such conduct as set forth in paragraphs (2)(a) through (d) of the Findings of Fact Section constitutes a violation of Section 4729.55(B) of the Ohio Revised Code (ORC), a laboratory as defined in section 3719.01 of the Revised Code will maintain supervision and control over the possession and custody of dangerous drugs that may be acquired by or on behalf of the applicant.

2. Such conduct as set forth in paragraphs (2)(a) through (d) of the Findings of Fact Section constitutes a violation of each of the following divisions of Section 4729.57 of the ORC:

   a. Violating any provision of this chapter, ORC Section 4729.57(A)(3); and

   b. Ceasing to satisfy the qualifications of a TDDD set forth in 4729.55 of the Revised Code, ORC Section 4729.57(A)(7).

3. Such conduct as set forth in paragraphs (2)(a), (2)(d) and (3) of the Findings of Fact Section constitutes a violation of each of the following divisions of Section 3715.63 of the ORC:
a. A drug is adulterated if it has been produced, processed, prepared, packed or held under unsanitary conditions whereby it may have been contaminated with filth, or whereby it may have been rendered injurious to health, ORC Section 3715.63(A)(2); and

b. It is a drug and its container is composed, in whole or in part, of any poisonous or deleterious substance that may render the contents injurious to health, ORC Section 3715.63(A)(3).

4. Such conduct as set forth in paragraphs (2)(a) through (d) of the Findings of Fact Section constitutes the following violations of Ohio Administrative Code Rule (OAC) 4729-13, approved laboratories:

a. The applicant is not qualified to conduct the business of an approved laboratory; OAC Rule 4729-13-03(A); and

b. Adequate safeguards are not assured to prevent the illegal acquisition, distribution, or utilization of dangerous drugs or their diversion into illicit channels, OAC Rule 4729-13-03(C); and

c. Records are not being kept in accordance with OAC Rule 4729-13-04; and

d. Controlled substances are not being stored in a securely locked, substantially constructed cabinet, OAC Rule 4729-13-05(B).

5. Such conduct as set forth in paragraph (2)(c) of the Findings of Fact Section constitutes a violation of Ohio Administrative Code Rule 4729-5-11(C)(6), Record keeping.

6. Such conduct as set forth in paragraphs (2)(a) and (2)(c) of the Findings of Fact Section constitutes a violation of Ohio Administrative Code Rule 4729-9-06, failure to conduct proper disposal of dangerous drugs which are controlled substances.

7. Such conduct as set forth in paragraphs (2)(a) through (d) the Findings of Fact Section constitutes a violation of Ohio Administrative Code Rule 4729-9-11, failure to maintain security and control of dangerous drugs.

8. Such conduct as set forth in paragraph (2)(c) of the Findings of Fact Section constitutes a violation of Ohio Administrative Code Rule 4729-9-14(B), failure to maintain proper records of controlled substances.

9. Such conduct as set forth in paragraphs (2)(a) through (d) the Findings of Fact Section constitutes a violation of Ohio Administrative Code Rule 4729-9-19(A)(4), failure to be of good moral character and habit.

10. Such conduct as set forth in paragraphs (2)(a) through (d) the Findings of Fact Section constitutes a violation of Ohio Administrative Code Rule 4729-9-22, failure to maintain proper Records of Dangerous Drugs.
Pursuant to Section 4729.57 of the Ohio Revised Code, and pursuant to Section 4729-9-01(E) of the Ohio Administrative Code, and after consideration of the record as a whole, the State of Ohio Board of Pharmacy adjudicates the matter of Toxicology Associates, Inc. as follows:

On the basis of the Findings of Fact and section (1) of the Conclusions of Law, the State of Ohio Board of Pharmacy hereby revokes permanently the Terminal Distributor of Dangerous Drugs License, No. 02-0076050, held by Toxicology Associates, Inc. effective as of the Board’s findings on January 10, 2017.

On the basis of the Findings of Fact and section (2) of the Conclusions of Law, the State of Ohio Board of Pharmacy hereby revokes permanently the Terminal Distributor of Dangerous Drugs License, No. 02-0076050, held by Toxicology Associates, Inc. effective as of the Board’s findings on January 10, 2017.

On the basis of the Findings of Fact and section (3) of the Conclusions of Law, the State of Ohio Board of Pharmacy hereby revokes permanently the Terminal Distributor of Dangerous Drugs License, No. 02-0076050, held by Toxicology Associates, Inc. effective as of the Board’s findings on January 10, 2017.

On the basis of the Findings of Fact and section (4) of the Conclusions of Law, the State of Ohio Board of Pharmacy hereby revokes permanently the Terminal Distributor of Dangerous Drugs License, No. 02-0076050, held by Toxicology Associates, Inc. effective as of the Board’s findings on January 10, 2017.

On the basis of the Findings of Fact and section (5) of the Conclusions of Law, the State of Ohio Board of Pharmacy hereby revokes permanently the Terminal Distributor of Dangerous Drugs License, No. 02-0076050, held by Toxicology Associates, Inc. effective as of the Board’s findings on January 10, 2017.

On the basis of the Findings of Fact and section (6) of the Conclusions of Law, the State of Ohio Board of Pharmacy hereby revokes permanently the Terminal Distributor of Dangerous Drugs License, No. 02-0076050, held by Toxicology Associates, Inc. effective as of the Board’s findings on January 10, 2017.

On the basis of the Findings of Fact and section (7) of the Conclusions of Law, the State of Ohio Board of Pharmacy hereby revokes permanently the Terminal Distributor of Dangerous Drugs License, No. 02-0076050, held by Toxicology Associates, Inc. effective as of the Board’s findings on January 10, 2017.

On the basis of the Findings of Fact and section (8) of the Conclusions of Law, the State of Ohio Board of Pharmacy hereby revokes permanently the Terminal Distributor of Dangerous Drugs License, No. 02-0076050, held by Toxicology Associates, Inc. effective as of the Board’s findings on January 10, 2017.

On the basis of the Findings of Fact and section (9) of the Conclusions of Law, the State of Ohio Board of Pharmacy hereby revokes permanently the Terminal
Distributor of Dangerous Drugs License, No. 02-0076050, held by Toxicology Associates, Inc. effective as of the Board’s findings on January 10, 2017.

On the basis of the Findings of Fact and section (10) of the Conclusions of Law, the State of Ohio Board of Pharmacy hereby revokes permanently the Terminal Distributor of Dangerous Drugs License, No. 02-0076050, held by Toxicology Associates, Inc. effective as of the Board’s findings on January 10, 2017.

The Board further orders Toxicology Associates, Inc. to pay to a monetary penalty in the amount of $10,000.00, by means of a cashier’s check made payable to “Treasurer, State of Ohio,” mailed with the enclosed form to the OSBP, 77 South High Street, 17th Floor, Columbus, Ohio 43215-6126, no later than 30 days from the effective date of this Order.

Ms. Yarosh moved for Findings of Fact; Ms. Marchal seconded the motion. Motion passed (Aye-6/Nay-0).

Mr. Wilt moved for Conclusions of Law; Ms. Yarosh seconded the motion. Motion passed (Aye-6/Nay-0).

Ms. Yarosh moved for Action of the Board; Mr. Passafume seconded the motion. Motion passed (Aye-6/Nay-0).

SO ORDERED.

ORDER VACATING THE JANUARY 12, 2017 ORDER OF THE STATE OF OHIO BOARD OF PHARMACY AND SETTING THE MATTER FOR HEARING (Case Number 2016-1519)

In The Matter Of:
Toxicology Associates, Inc.
999 Bethel Road
Columbus, Ohio 43214
TDDD No. 02-0076050

On November 29, 2016, the State of Ohio Board of Pharmacy (Board) issued a Notice of Opportunity for Hearing of Proposed Disciplinary Action (Notice) in the matter of Toxicology Associates, Inc., License Number 02-0076050. As of the thirtieth day after mailing pursuant to Section 119.07 of the Revised Code, the Board had not received a request for a hearing from Toxicology Associates, Inc. Accordingly, the matter was set before the Board pursuant to Goldman v. State Med. Bd. and heard on January 10, 2017. On January 12, 2017, the Board issued its Order in the matter and served Toxicology Associates, Inc., with its Order. Upon receipt of the January 12, 2017 Order, the Board received communication from Benjamin Corpus, the owner/operator of Toxicology Associates, Inc. indicating he had requested a hearing on December 27, 2016 as instructed in the Notice letter via email.

ORDER VACATING THE JANUARY 12, 2017 ORDER OF THE STATE OF OHIO BOARD OF PHARMACY AND SETTING THE MATTER FOR HEARING
After consultation with the Board’s Information Technology Department, Toxicology Associates, Inc.’s request for a hearing dated December 27, 2016 was located in a spam e-mail folder. As such, this Board hereby vacates its Order dated January 12, 2017 and grants Toxicology Associates, Inc. a hearing in this matter as to the allegations set forth in the Notice letter dated November 29, 2016. A scheduling letter with a new hearing date will be sent to Toxicology Associates, Inc.

R-2017-241  Ms. Marchal moved that the Board Meeting Minutes of December 5-6, 2016 are approved as written. The motion was seconded by Ms. Yarosh and approved by the Board: Aye-6.

10:36 a.m.  The Board discussed the InPower Personal Medication Assistant presented by Cardinal Health at yesterday’s meeting.

R-2017-242  Mr. Weaver moved that the meeting be adjourned. The motion was seconded by Mr. Passafume and approved by the Board: Aye-6.

10:43 a.m.  The meeting was adjourned.

1:30 p.m.  The following candidates for licensure by reciprocity participated in a discussion of pharmacy laws and rules with Ms. Terri Ghittman, OARRS Pharmacist, in Room South A, 31st Floor of the Vern Riffe Center for the Government and the Arts:

- KRISTEN LEIGH AMMAY  CALIFORNIA
- JEFF A. BATES  MICHIGAN
- DAVID JOSEPH BLANZY  FLORIDA
- SHELLEY ANNETTE BROWN  INDIANA
- JESSICA SHU-SHUAN CHEN  TEXAS
- KELLI ANN CONNER  ILLINOIS
- DANIELLE E. DUNLAP  ARIZONA
- JORDAN SHEA GOETZKE  TENNESSEE
- KYLE RYAN GRIMSLID  TEXAS
- LAUREN HOVAN  MASSACHUSETTS
- BRIAN ANDREW KUEHNE  KENTUCKY
- HONG T. LAM  ILLINOIS
- BONI-SUE LANINFA  MASSACHUSETTS
- PIO JUAN DAVID LANSANGAN  CALIFORNIA
- ANDREA M. LINDERS  ILLINOIS
- JON THEODORE MCCLYMONT  NEBRASKA
- CARLA MCFADDEN  INDIANA
- RYUN SCHOEFIELD MCKENZIE  FLORIDA
- SATENDRA H. PATEL  MICHIGAN
- TALLIE LENORE PEDERSON  NEVADA
- CHELSEA REGINA PEKNY  INDIANA
- JEREMY JAMES PRUNTY  WEST VIRGINIA
- NATHANIEL RYAN REPINE  INDIANA
- NICHOLAS AARON ROBINSON  WEST VIRGINIA
- SHARMEEN Y. ROY  TEXAS